Give us a Call
+1 (915) 412-6680
Send us a Message
[email protected]
Opening Hours
Mon-Thu: 7 AM - 7 PM
Fri - Sun: Closed

GLP-1 Receptor Agonist Insights for Metabolic Health

Understand how GLP-1 receptor agonists for metabolic health can enhance your lifestyle and support metabolic function effectively.

Abstract

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I guide you through the evolution, mechanisms, clinical evidence, safety considerations, perioperative care, drug interactions, and practical, long-term use of GLP-1 receptor agonists and the dual GLP-1/GIP agent tirzepatide. Drawing from landmark trials and consensus statements, I explain how these therapies improve weight, glycemia, cardiovascular, and kidney outcomes, why side effects occur, and how to prevent discontinuation. I show how integrative chiropractic care enhances autonomic balance, mitigates pain, preserves lean mass, and supports gastrointestinal tolerance—turning pharmacology into durable, whole-person improvement. You will learn when to choose each agent, how to titrate safely, how to personalize plans for special populations, and how to weave together resistance training, nutrition, breathwork, sleep, and manual therapy for sustained results. I close with clinical observations from my practice to help translate research into patient-centered care.

Why GLP-1 Therapies Matter Now for Obesity and Cardiometabolic Health

Obesity affects over 40% of U.S. adults and drives risk for type 2 diabetes, cardiovascular disease, chronic kidney disease, sleep apnea, osteoarthritis, and several cancers. When lifestyle alone is not enough, modern incretin-based therapies provide high-impact, evidence-backed tools to reduce caloric intake, improve glycemic control, and lower cardiometabolic risk.

  • GLP-1 receptor agonists have become first-line agents in diabetes care and are increasingly central to chronic weight management due to their robust effects on A1C and weight.
  • Dual agonists like tirzepatide amplify effects by engaging GIP alongside GLP-1, often resulting in greater weight loss and improved glycemic control.
  • Integrative practice models—combining chiropractic care, movement, nutrition, and behavioral strategies—help patients maintain function, preserve lean mass, and translate weight loss into daily-life gains.

My goal is simple: equip you to use these therapies confidently and safely, while integrating musculoskeletal and autonomic strategies that make results stick.

Key Terminology and Why These Hormones Matter

  • GLP-1 receptor agonists: Medications that activate the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon, slowing gastric emptying, reducing appetite, and modulating reward circuits. Examples: exenatide, liraglutide, dulaglutide, semaglutide.
  • GIP (glucose-dependent insulinotropic polypeptide): An incretin that enhances insulin secretion; co-agonists that stimulate GIP and GLP-1 receptors (e.g., tirzepatide) can produce synergistic metabolic effects.
  • Glucagon (GCG): Beyond counter-regulating insulin, glucagon influences hepatic glucose output, energy balance, and lipid metabolism. Triple agonists (GLP-1/GIP/glucagon) aim to increase energy expenditure and fat oxidation.
  • Nutrient-stimulated hormone therapies (NUSH): An umbrella for therapies mimicking endogenous gut-hormone responses to food, including GLP-1 and GIP agents.

These terms frame how incretin therapies act across multiple organ systems to deliver outcomes that matter: improved glycemia, reduced appetite, lower weight, and protection for the heart and kidneys.

Mechanisms of Action: The Physiology Behind the Benefits

GLP-1 receptors are widely expressed. Their distribution explains the breadth of clinical benefits and guides how we anticipate and manage effects.

  • Pancreas
    • Beta cells: GLP-1 signaling raises cAMP and activates PKA/Epac, leading to glucose-dependent insulin secretion. Because secretion is tied to ambient glucose levels, these agents have a lower risk of hypoglycemia than non–glucose-dependent secretagogues. Chronic signaling may support beta-cell survival in preclinical models, potentially slowing decline.
    • Alpha cells: GLP-1 suppresses inappropriate glucagon release during hyperglycemia, reducing hepatic gluconeogenesis and glycogenolysis, thereby improving fasting and postprandial glycemia.
  • Gastrointestinal Tract
    • Gastric emptying: GLP-1 slows gastric emptying through vagal and enteric pathways, reducing the rate of glucose appearance and increasing early satiety. Clinically, this lowers postprandial glucose spikes and reduces caloric intake.
    • Satiety signaling: Gut-brain communication via vagal afferents and hindbrain nuclei enhances fullness and reduces meal size.
  • Central Nervous System
    • Hypothalamus: GLP-1 acts on the arcuate and paraventricular nuclei, modulating POMC/CART (anorexigenic) and NPY/AgRP (orexigenic) neurons to reduce appetite.
    • Reward circuitry: Activity in the ventral tegmental area and nucleus accumbens is attenuated, blunting the dopamine reward response to hyperpalatable foods. Patients often describe reduced “food noise,” helping sustain dietary changes.
  • Cardiovascular and Renal Systems
    • Endothelium and vasculature: GLP-1 signaling improves endothelial function, reduces inflammation and oxidative stress, and may modulate blood pressure via natriuresis.
    • Kidney: GLP-1 agents reduce albuminuria and slow eGFR decline in at-risk populations via hemodynamic and anti-inflammatory mechanisms.

Why this matters: When we lower A1C without frequent hypoglycemia, patients feel and function better. Appetite suppression paired with slower gastric emptying reduces energy intake. Reward-circuit modulation tackles binge and late-night cravings. Cardio-renal protection delivers benefits beyond weight and glucose.

From Lizard Peptides to Long-Acting Analogs: The Trajectory of Innovation

  • Early discovery: Incretin biology matured in the 1980s, with the identification of GLP-1 and GIP as nutrient-responsive hormones.
  • First-to-market: Exenatide (Byetta), modeled on exendin-4 from Gila monster saliva, launched in 2005—an early example of nature-inspired pharmacology.
  • Human analogs and weekly dosing: Liraglutide (2009) and later extended-release exenatide (2012) improved convenience and adherence.
  • Semaglutide era: Weekly semaglutide (2017; oral formulation in 2019) advanced A1C and weight outcomes and earned chronic weight management approval as Wegovy (2021).
  • Dual agonism: Tirzepatide (2022) combined activation of the GIP and GLP-1 receptors, achieving unprecedented weight and glycemic outcomes.
  • What’s next: Development includes triple agonists, monthly injectables, longer-acting oral agents, and combinations with amylin analogs to optimize tolerability, efficacy, and adherence.

Evidence Highlights: What the Strongest Trials Show

  • Weight and Glycemic Control
    • Liraglutide SCALE: ~8% mean weight loss at 56 weeks with improved cardiometabolic markers (Pi-Sunyer et al., 2015).
    • Semaglutide STEP:
      • STEP 1: ~15% mean weight loss at 68 weeks in adults with overweight/obesity (Wilding et al., 2021).
      • STEP 2: ~9.6% mean weight loss with A1C reductions of ~1.6–2.0% in type 2 diabetes (Davies et al., 2021).
      • STEP 5: >13% mean weight loss beyond one year, supporting durability (Rubino et al., 2022).
    • Tirzepatide SURMOUNT: 15–20% mean weight loss at 72 weeks; some cohorts approach ~25% (Jastreboff et al., 2022; Frias et al., 2023).
  • Cardiovascular and Renal Outcomes
    • Semaglutide SELECT: ~20% reduction in 3-point MACE in adults with obesity and established cardiovascular disease but without diabetes—hard cardiovascular benefits in a non-diabetic population (Nissen et al., 2023).
    • HFpEF with obesity: Semaglutide improved heart failure symptoms, physical limitations, and exercise capacity (Kitzman et al., 2023).
    • Kidney outcomes: Semaglutide reduced a composite kidney outcome by ~22% among patients with obesity and cardiovascular disease (Mann et al., 2021).

In practice, I align therapy with top patient goals—glycemia, weight, heart/kidney protection—and pair medication with structured nutrition and resistance training to preserve lean mass and function.

Safety Profile: Adverse Effects and How to Mitigate Them

Early gastrointestinal effects reflect pharmacodynamic changes (delayed gastric emptying, central satiety) and typically improve with slow titration.

  • Common effects
    • Nausea, vomiting, diarrhea, abdominal discomfort, dyspepsia, decreased appetite.
    • Taste changes or aversion to fried/greasy foods
  • Less common but important
    • Gastroparesis or bowel obstruction risk in those with severe baseline dysmotility
    • Pancreatitis: monitor for persistent severe upper abdominal pain radiating to the back
    • Gallbladder disease: cholelithiasis/cholecystitis risk during rapid weight loss
    • Acute kidney injury: dehydration from vomiting; protect hydration and monitor renal function
    • Hypoglycemia: mainly with concurrent insulin or sulfonylureas; proactively reduce doses
    • Diabetic retinopathy: rapid A1C drops can transiently worsen retinopathy; coordinate care
    • Body composition: risk of lean mass loss; prioritize protein and resistance training
  • Contraindications and boxed warning
    • Thyroid C-cell tumors: contraindicated with personal/family history of MTC or MEN2
    • Avoid in severe GI disease, history of pancreatitis, pregnancy, or breastfeeding.
  • Patient counseling essentials
    • Explain theoretical thyroid risk and symptoms (neck mass, dysphagia, hoarseness, dyspnea)
    • Routine calcitonin or thyroid ultrasound screening is not recommended in asymptomatic users.
    • Avoid compounded products; stick to FDA-approved medications dispensed by licensed pharmacies.

Dosing Strategies: Why “Start Low, Go Slow” Works

The biology is clear: early GI symptoms represent intended effects on gastric emptying and satiety. The nervous system adapts over weeks. We protect adherence by moving at the body’s pace.

  • Begin at the lowest dose and extend titration steps if moderate nausea or early satiety interferes with intake.
  • Encourage small, protein-forward meals; limit high-fat, fried, and very sweet foods, which can exacerbate nausea.
  • Promote hydration and electrolytes, especially during the first 8–12 weeks.
  • Pair with resistance training immediately to signal lean mass retention.
  • If adding to insulin or sulfonylureas, proactively reduce those agents and monitor with CGM when available.

Perioperative Care: GLP-1 Use and Aspiration Risk

Consensus statements from anesthesiology and gastroenterology groups (2024) indicate that most patients can continue GLP-1 therapy before procedures. For high GI risk (marked nausea, vomiting, gastroparesis), a pre-procedural liquid diet mitigates aspiration risk.

  • Ask specifically about GLP-1 use during pre-op assessments.
  • Screen for GI symptoms and gastroparesis.
  • Coordinate with anesthesia on individualized liquid diet plans and NPO timing.
  • Resume standard dosing post-operatively once oral intake and hydration normalize.

Delaying gastric emptying is part of how these drugs work; perioperative plans must respect this physiology while balancing airway safety.

Major Drug Interactions Clinicians Must Check

  • Insulin and Sulfonylureas
    • Risk: additive hypoglycemia
    • Strategy: proactively reduce doses, monitor SMBG/CGM
  • Narrow Therapeutic Index Drugs
    • Mechanism: delayed gastric emptying can alter absorption
    • Examples: certain antiepileptics, warfarin (monitor INR), select immunosuppressants
    • Strategy: intensified monitoring during initiation/up-titration; adjust timing or formulation
  • Tirzepatide and Oral Contraceptives
    • Guidance: Use non-oral contraception for 4 weeks after initiation and each dose escalation
  • DPP-4 inhibitors
    • Evidence: combining DPP-4 inhibitors with GLP-1 agonists adds side effects without benefit; avoid combination per ADA guidance

Public Health Safety: Counterfeit and Unregulated Online Sales

Counterfeit or “research use only” GLP-1 products marketed online pose serious risks: contamination, mislabeled doses, or entirely different compounds. Dosing errors can trigger severe GI events, dehydration, or destabilize glycemia.

  • Educate patients to use only FDA-approved medications via licensed pharmacies.
  • Verify NDC codes, lot numbers, and pharmacy licensure.
  • Document counseling and sourcing verification.

In my clinics, atypical adverse reactions have resolved once verified formulations were used.

FDA Safety Monitoring: Suicidal Ideation Reports Under Evaluation

In 2024, the FDA began evaluating reports of suicidal ideation among users of GLP-1 agents and tirzepatide. No causal link has been established, but vigilance is appropriate.

  • Baseline screening for mood, suicidality, and eating disorders
  • Repeat checks after each dose escalation and at quarterly maintenance visits
  • Collaborate with behavioral health; protect sleep and circadian regularity

Appetite suppression and rapid weight change intersect with mood pathways; proactive monitoring supports safety and adherence.

Long-Term Use: Why Continuing Therapy Matters

Obesity is a chronic, relapsing disease with hypothalamic set points, adipocyte signaling, and metabolic adaptation. Discontinuation often leads to a regain.

  • STEP 1 extension: After discontinuing semaglutide, participants regained roughly two-thirds of the weight lost at one year (Rubino et al., 2022).
  • SURMOUNT-4: Continuing tirzepatide maintained losses; switching to placebo led to ~14% weight regain by week 52 (Jastreboff et al., 2023).

Interpretation: Long-term pharmacotherapy—such as antihypertensives—helps maintain gains in weight, glycemia, and risk reduction. Maintenance plan.

Discontinuation: Why Patients Stop and How to Prevent It

Real-world discontinuation can be high in the first year. Top drivers include adverse effects, cost, access gaps, and unmet expectations.

  • Start low, go slow; hold dose increases when symptoms arise.
  • Front-load education on expected GI effects and management strategies.
  • Build multidisciplinary support: dietitians, pharmacists, behavioral health, and integrative clinicians.
  • Offer coverage, navigation, and consider manufacturer assistance.

Adherence is a physiologic outcome—patients stay the course when symptoms are managed, costs are addressed, and goals feel meaningful.

Guideline Alignment: Where GLP-1 Therapies Fit

  • Diabetes (ADA, AACE): Recommend GLP-1 receptor agonists for patients with type 2 diabetes who have or are at high risk for ASCVD, CKD, HF, obesity, or MASLD. Focus on cardiometabolic risk beyond A1C (American Diabetes Association, 2024; American Association of Clinical Endocrinology, 2023).
  • Obesity (ACC): GLP-1 agents are first-line pharmacotherapy for weight management without requiring lifestyle “failure,” given their superior efficacy compared with lifestyle alone and a lower risk than bariatric surgery for many patients (American College of Cardiology, 2024).

Personalizing Therapy: Matching the Agent to the Patient

  • Type 2 diabetes with ASCVD: Favor agents with proven MACE reduction (e.g., semaglutide); coordinate with cardiology.
  • CKD or albuminuria: GLP-1 RAs offer renal benefits; monitor eGFR; consider SGLT2 inhibitors for additive renal/HF protection.
  • History of gallbladder disease: Titrate slowly, promote steady calorie deficits, and monitor biliary symptoms.
  • GI motility concerns: Avoid or use extreme caution with baseline gastroparesis.
  • Reproductive planning: Avoid during pregnancy and breastfeeding; counsel on contraception; with tirzepatide, avoid oral contraceptives during initiation and dose escalations.
  • Co-therapy with insulin/sulfonylureas: Reduce doses and use CGM to minimize hypoglycemia.

Integrative Chiropractic Care: Amplifying Outcomes and Preserving Function

As a clinician working at the intersection of neuromusculoskeletal medicine and metabolic health, I integrate chiropractic modalities alongside GLP-1 therapy to improve adherence, comfort, and functional capacity.

  • Chiropractic and neuromusculoskeletal support
    • Spinal and extremity adjustments optimize joint mechanics and reduce nociceptive drive, making early exercise more comfortable. Less pain improves sleep and autonomic balance, which supports glycemic control and fat loss.
    • Soft-tissue therapies and myofascial release address compensations and movement restrictions that can worsen with rapid weight change, improving range of motion and exercise tolerance.
    • Neurodynamic and proprioceptive training enhance motor control and balance, enabling safe progression to resistance training, which is essential for preserving lean mass.
  • Exercise and body composition
    • Focus on progressive resistance training (2–4 sessions/week) with compound movements; phase in isometrics and closed-chain exercises when pain or mobility limits exist.
    • Build Zone 2 aerobic base to support mitochondrial health, insulin sensitivity, and recovery without driving excessive hunger.
    • Track functional benchmarks (sit-to-stand reps, loaded carries, gait speed) to reinforce adherence.
  • Nutrition and recovery
    • Protein-first meals: Target 1.2–1.6 g/kg/day to preserve lean mass and mitigate hunger variability; use protein shakes or Greek yogurt plus electrolytes when appetite is low.
    • Emphasize micronutrient density: potassium, magnesium, and omega-3s to support cardiometabolic health and reduce cramping.
    • Meal pacing aligns with delayed gastric emptying and reduces the risk of nausea.
  • Autonomic regulation and behavior
    • Diaphragmatic breathing and brief HRV-guided practices before meals improve GI comfort and reduce stress-eating triggers.
    • Sleep optimization helps stabilize hunger hormones (ghrelin and leptin) and improves glucose control.
    • Cognitive-behavioral frameworks help patients leverage reduced food noise and build new routines.

Physiologic coherence: Pain reduction lowers sympathetic drive; movement sends mechanotransduction signals to muscle and bone; autonomic balance enhances vagal inputs that support gastric motility and satiety. Integrative care makes GLP-1 therapy more tolerable and more effective.

Clinical Observations from My Practice

From my work shared at Chiromed.com and my professional collaborations:

  • Initiating GLP-1 therapy alongside structured resistance training and pain-modulating manual care reduces fatigue and improves willingness to train, protecting lean mass and posture during weight loss.
  • Neck and low-back discomfort may transiently flare as body mass redistributes; timely adjustments and soft-tissue work smooth transitions and prevent activity drop-off.
  • Simple breathwork before meals reduces GI complaints and improves pacing, suggesting autonomic co-regulation complements delayed gastric emptying.
  • The most durable changes occur when we measure function—gait speed, grip strength, sit-to-stand improvements—rather than focusing only on the scale.

For more of my clinical insights and interprofessional collaborations, visit:

Case Study: Re-Initiating Semaglutide Safely After an Interruption

Patient: Amanda Chen, 58, T2D, BMI 36, osteoarthritis. Previously tolerated semaglutide at 1.7 mg weekly, lost 12 lbs, then paused therapy for six weeks due to GI illness. She wants to restart at 1.7 mg.
Clinical reasoning: Even after prior tolerance, restarting at a high dose post-gap increases the risk of GI side effects due to resetting of gastric emptying and gut–brain signaling.
Best practice:

  • Restart at 0.25 mg weekly for 4 weeks, then re-titrate per standard protocol:
    • 0.25 mg weekly × 4 weeks
    • 0.5 mg weekly × 4 weeks
    • 1.0 mg weekly × 4 weeks
    • 1.7 mg weekly × 4 weeks (if indicated for weight)
    • 2.4 mg weekly (target for obesity indications), pacing individualized
  • If adverse effects occur: pause escalation; maintain dose longer until tolerance improves.

Monitoring:

  • During titration: monthly visits to assess GI effects, hydration, weight change, glycemia, blood pressure, and adherence.
  • Maintenance: quarterly follow-up; more frequent if combining with insulin or in older adults with CKD risk.

Safety parameters:

  • Glycemia: SMBG/CGM; reduce insulin/sulfonylurea doses to prevent hypoglycemia.
  • Renal: serum creatinine/eGFR; ensure hydration, especially if vomiting/diarrhea or diuretic use.
  • Pancreatitis: persistent upper abdominal pain and vomiting; check lipase promptly.
  • Gallbladder: RUQ pain; consider ultrasound if symptomatic.
  • Thyroid/MTC risk: screen personal/family history for MEN2/MTC.
  • Mental health: mood checks and suicidality screening during escalations and milestones.

Counseling for GI tolerance:

  • Hydration: 2–3 liters/day unless contraindicated; separate fluids from meals if reflux is prominent.
  • Meal structure: smaller, protein-forward, nutrient-dense meals; avoid large, high-fat/fried meals early.
  • Triggers: limit carbonation and alcohol; avoid lying down after meals.
  • Constipation plan: fiber, magnesium citrate or osmotic laxatives as needed, daily walking.
  • Nausea strategies: ginger tea, cooled foods, bland starters; consider dose holds rather than reductions when symptoms are transient.
  • Expectations: normalize mild GI effects; reinforce adherence.

Adaptations:

  • Low responders (<5% weight loss at 12–16 weeks): verify adherence, timing, nutrition, sleep; consider longer holds at intermediate doses or switching agents if the maximally tolerated dose yields inadequate response.
  • Excessive responders (frailty, BMI <18.5, low protein intake): evaluate for endocrinopathies, malabsorption, or disordered eating; reduce dose or pause; engage dietitian and behavioral health.

Eating Right to Feel Better- Video

Integrative Nutrition: The MEAL Framework

Nutrition is integral to efficacy and safety; I use the MEAL framework:

  • M: Muscle maintenance
    • Set protein targets at 1.2–1.6 g/kg/day to preserve lean mass.
    • Pair with resistance training to counter sarcopenia and sustain resting metabolic rate.
  • E: Energy balance
    • Align caloric intake with satiety cues; maintain micronutrient sufficiency.
    • Spread intake throughout the day to stabilize energy and blood glucose levels.
  • A: Avoid side effects
    • Constipation: fiber, fluids, magnesium, or PEG as needed, daily movement.
    • Nausea/GERD: small portions, low-fat cooking, avoid carbonation and late meals; consider short-term H2 blockers or PPIs when necessary.
  • L: Liquid intake
    • 2–3 liters/day supports motility and reduces dizziness/fatigue from reduced intake; add electrolytes with physical activity or heat exposure.

Movement and Resistance Training: Protecting Lean Mass and Metabolic Rate

Exercise prescriptions should be specific and progressive:

  • Aerobic baseline: build toward 150 minutes/week moderate intensity or 75 minutes/week vigorous.
  • Resistance training: 60–90 minutes/week over 2–3 sessions to stimulate muscle protein synthesis.
  • Daily movement: 30–60 minutes of light-to-moderate activity supports glycemic control and GI motility.
  • Balance and mobility are essential in older adults; they reduce fall risk and support independence.
  • Functional measures: grip strength and 6-minute walk tests track resilience and guide load.

This protects lean mass, stabilizes metabolism, and makes pharmacologic weight loss translate into better function.

Practical Clinical Pearls: What Works Best

  • Start with the why: match therapy choice to indications—T2D, obesity, ASCVD risk, CKD, MASLD—and articulate goals beyond A1C.
  • Dosing discipline: start low, go slow; hold at a dose rather than escalate into intolerance.
  • Education first: teach injection technique, site rotation, and what to expect in the first 4–8 weeks.
  • Prevent hypoglycemia: down-titrate insulin or sulfonylureas; use CGM when available.
  • Watch gallbladder and pancreas: RUQ pain or persistent nausea warrants evaluation; check lipase and consider ultrasound.
  • Renal protection: monitor eGFR, especially if vomiting or diuretic use is present; emphasize hydration.
  • Reproductive safety: avoid in pregnancy and lactation; counsel on contraception. With tirzepatide, avoid oral contraceptives for 4 weeks after start/escalation.
  • Thyroid precautions: screen for MTC/MEN2 history; discuss boxed warning implications.
  • Expectation management: set a realistic pace for weight loss; focus outcomes on function, labs, and cardiometabolic risk.
  • Team-based care: dietitians, diabetes educators, pharmacists, behavioral health, and integrative clinicians raise success and reduce discontinuation.

Common Pitfalls to Avoid

  • Rapid escalation: rushing doses leads to dropout; titration patience preserves adherence.
  • Insufficient counseling: early discontinuation is preventable with anticipatory guidance.
  • Overlooking interactions: reassess narrow-therapeutic-index drugs, insulin/sulfonylurea dosing, and contraception with tirzepatide.
  • Hydration gaps: many symptoms improve with fluids and electrolytes; formalize targets.
  • Missing pancreatitis signals: persistent or escalating abdominal pain deserves prompt workup.
  • Skipping thyroid/MEN2 screening: maintain vigilance given labeled risks.
  • Scale-only thinking: anchor goals in function, labs, and risk, not just pounds.
  • Cost surprises: verify coverage, explore assistance, plan contingencies.
  • Social determinants: address food access, transportation, and home stability.
  • Set-and-forget: active monitoring is essential during the first 3–6 months and after dose changes.

Putting It All Together: A Patient-Centered, Integrative Roadmap

  • Verify medication source; prescribe only FDA-approved products via licensed pharmacies.
  • Screen for mood/eating disorders, pancreatitis/gallbladder risks, MEN2/MTC history.
  • Plan insulin/sulfonylurea reductions, CGM/SMBG, hydration, and nutrition strategies.
  • Initiate semaglutide at 0.25 mg weekly for 4 weeks; escalate only when tolerated.
  • Build a nutrition plan using the MEAL framework with protein targets and micronutrient sufficiency.
  • Prescribe movement: progressive aerobic minutes, resistance training 2–3 days/week, plus balance and mobility.
  • Integrate chiropractic care for autonomic regulation, pain control, and kinetic chain optimization.
  • Schedule monthly check-ins during titration; quarterly thereafter; more frequent if medically complex.
  • Prepare for surgery by collaborating with anesthesia; use liquid diet protocols for high-risk cases.
  • Reassess response at 12–16 weeks; adapt the dose or switch agents as needed; always align with patient goals and values.

By weaving together pharmacology, lifestyle medicine, and integrative chiropractic strategies, we make GLP-1 therapies safer, more tolerable, and longer-lasting—delivering the cardiometabolic benefits patients deserve while preserving function and quality of life.

References

SEO tags: GLP-1 receptor agonists, semaglutide, tirzepatide, incretin therapy, obesity treatment, weight loss medication, type 2 diabetes, cardiovascular outcomes, kidney protection, SURMOUNT trials, STEP trials, SELECT trial, integrative chiropractic care, manual therapy, resistance training, satiety hormones, gastric emptying, reward circuitry, pancreatitis risk, gallbladder disease, boxed warning, MTC, MEN2, gastroparesis, A1C reduction, evidence-based medicine, functional medicine, body composition, lean mass preservation, chronic pain and obesity, HFpEF and obesity, perioperative GLP-1 management, drug interactions GLP-1, oral contraceptives tirzepatide, DPP-4 inhibitors, hydration, MEAL framework nutrition, autonomic balance, vagal tone, case study semaglutide restart, dose titration, ADA guidelines, AACE guidelines, ACC consensus, counterfeit Ozempic, FDA safety communication

PRP Injections and Their Benefits for Osteoarthritis

Discover the potential of PRP injections for osteoarthritis treatment and its role in promoting healing and reducing inflammation.

Abstract

As a clinician dedicated to integrative and evidence-based care, I frequently encounter patients suffering from knee osteoarthritis (OA) who are seeking relief. The decision on which injectable treatment to use can be complex, involving a delicate balance of providing rapid pain relief, ensuring long-term joint health, and considering the patient’s individual needs and goals. In this educational post, I will guide you through the latest research on common intra-articular injections for knee OA. We will begin by examining the role and significant risks of corticosteroids, exploring why the medical community is moving toward alternatives. I will then introduce ketorolac, an NSAID injection, as a safer, fast-acting alternative for acute flares. We’ll delve into the science of hyaluronic acid (HA), or viscosupplementation, evaluating its potential for longer-term benefits and its current standing in clinical guidelines. Finally, we will explore the exciting and robust evidence supporting Platelet-Rich Plasma (PRP) as a treatment that not only manages pain but also shows promise as a disease-modifying therapy capable of delaying the need for surgery. Throughout this discussion, I will integrate my clinical observations and emphasize how an integrative chiropractic approach, focusing on biomechanics and holistic patient care, complements these advanced treatments to optimize outcomes for our patients.


Hello, I’m Dr. Alexander Jimenez. With my extensive background in chiropractic and functional medicine, holding titles such as DC, APRN, FNP-BC, CFMP, IFMCP, ATN, and CCST, my practice is rooted in a deep commitment to providing integrative care grounded in the latest scientific evidence. Today, I want to take you on a journey through the landscape of injectable treatments for knee osteoarthritis, a condition I see daily in my clinic. We’ll examine what the research tells us and how we can make the best choices for our patients.

Let’s begin with a common clinical scenario to frame our discussion.

A Common Clinical Scenario: The Acute Knee OA Flare

Imagine a 60-year-old woman who comes into my office with an acute flare-up of her right knee pain. She was diagnosed with mild osteoarthritis two years prior and had managed it well with physical therapy and weight loss. She remains quite active, but this current flare started after a bit more walking than usual. There was no specific injury or trauma. She presents with mild swelling, and her pain is most pronounced when using stairs. Her son’s wedding is just a week away, and she is understandably anxious, requesting an injection to improve her pain and mobility for the event.

On examination, she has a mild antalgic gait (walking with a limp to avoid pain), tenderness along the medial joint line, and a small effusion (swelling within the joint). Her X-rays confirm tricompartmental osteoarthritis with a Kellgren-Lawrence (K-L) grade of 2, which is considered mild to moderate.

So, we have a patient with an acute OA flare, no history of prior injections, and a significant life event approaching. What is the best way to help her? The most conventional response in many practices would be an intra-articular corticosteroid injection. But is that the right answer? My goal today is not to give you a single “correct” answer but to arm you with the evidence so you can make an informed decision, one that aligns with the principles of modern, evidence-based care.

The Double-Edged Sword of Corticosteroid Injections

Why Corticosteroids are so Common

There’s a clear reason why corticosteroids have been the go-to for decades. The primary driver of pain and swelling in an OA flare is synovial inflammation. Corticosteroids are potent anti-inflammatory agents. They work by:

  • Suppressing the infiltration of leukocytes (white blood cells) into the joint.
  • Decreasing the activity of local immune cells within the synovium (the soft tissue lining the joint).
  • Downregulating the expression of genes involved in the inflammatory cascade.

This powerful anti-inflammatory effect leads to decreased synovial membrane inflammation and a reduction in the effusion. The result is rapid pain relief, typically occurring within three to seven days. For our patient with the wedding next week, this timeline is very appealing. While oral NSAIDs or steroids could be considered, they carry significant systemic risks that an injection helps to minimize.

The Mounting Evidence Against Corticosteroids

Despite the short-term benefits, a growing body of evidence urges caution. There is significant concern for chondrotoxicity, meaning the substance is toxic to cartilage cells. Preclinical studies have provided robust evidence that steroids exert dose-dependent deleterious effects on cartilage morphology, histology, and viability. Simply put, the higher the dose of the steroid, the more damage it can cause to the cartilage. Among the different types, dexamethasone and triamcinolone appear to be the least toxic, but the risk remains.

This isn’t just a finding in lab studies. High-level clinical trials support these concerns. A pivotal study published in JAMA in 2017 was a two-year, randomized, placebo-controlled trial comparing injections of triamcinolone to saline in patients with knee OA (McAlindon et al., 2017). Patients received an injection every 12 weeks. The findings were startling:

  • There was no significant difference in pain relief between the steroid group and the placebo (saline) group over the two years.
  • The group receiving repeated steroid injections experienced significantly greater cartilage volume loss compared to the placebo group.

Another powerful retrospective review of over 49,000 patients, published in 2019, found that patients who received even one to three steroid injections (for various hip or knee conditions, not just OA) had a twofold greater risk of needing a knee replacement at the five-year mark (Kompel et al., 2019). The study also revealed a dose-dependent relationship: the risk of total knee arthroplasty (TKA) increased with each subsequent injection.

In my clinical practice at ChiroMed, I’ve observed this pattern. Patients who have received multiple steroid injections over the years often present with more advanced degenerative changes on their imaging than their symptom history might suggest. This is why there is a strong call within the medical community to find safer alternatives. While a single, first-time injection for an acute flare might seem reasonable, we must ask ourselves if we are sacrificing long-term joint health for short-term relief.

Ketorolac: A Safer, Fast-Acting Alternative for Knee Flares

If we want to avoid the chondrotoxic effects of steroids but still provide rapid relief for a patient like the one we discussed, where do we turn? I want to present an excellent alternative: ketorolac.

Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that can be injected directly into the joint. Its mechanism of action is different from and safer than corticosteroids:

  • As a COX-1 and COX-2 inhibitor, it blocks prostaglandin production, which is a key mediator of inflammation and pain sensitization.
  • Delivering it locally via injection achieves a high concentration in the synovial fluid, providing potent anti-inflammatory effects with minimal systemic exposure compared with oral NSAIDs.
  • Crucially, ketorolac provides anti-inflammatory and analgesic effects without the immunosuppressive and gene-expression-altering effects of steroids.

Most importantly, preclinical models have not shown the deleterious structural effects on cartilage that we see with steroids. Its onset of action is similar, within a few days, and its efficacy often lasts for a few months.

A 2021 systematic review and meta-analysis confirmed that, for knee and hip OA, an intra-articular ketorolac injection provides pain and functional improvements similar to those of corticosteroids from one week to three months post-injection, with minimal adverse events (Saltzman et al., 2021). Our own research has echoed these findings. In a study we conducted on hip pathologies, including OA, we found a trend toward greater pain improvement in the ketorolac group, which was statistically significant for the OA patients. The onset of relief was rapid (around 3 days for ketorolac), and the duration was comparable to that of steroids.

Therefore, ketorolac stands out as a fantastic steroid-sparing option. It addresses the same goal—rapid relief from an inflammatory flare—without the known cartilage toxicity. However, we must still be cautious and avoid its use in patients with contraindications to NSAIDs, such as a history of gastrointestinal ulcers, severe cardiac or kidney disease, or those on anticoagulants.

Hyaluronic Acid for Long-Term Joint Health

What if our patient doesn’t have an acute flare? What if they present with more chronic, persistent pain and want to improve the long-term health of their joint? This is where we shift our focus from just putting out the fire of inflammation to improving the joint’s structural environment. A primary candidate for this goal is hyaluronic acid (HA), also known as viscosupplementation.

The core concept behind HA injections is to augment the natural viscoelastic properties of the synovial fluid. In an osteoarthritic joint, the natural endogenous HA is depleted and degraded. This reduces the fluid’s viscosity and lubricating properties. By supplementing it with an injection, we aim to:

  • Improve joint lubrication and shock absorption.
  • Modulate nociception (pain signaling) and inflammation.

HA works through several biological pathways. It binds to a receptor on synovial cells, CD44, which in turn helps modulate inflammation by decreasing inflammatory cytokines such as IL-1β and cartilage-degrading enzymes such as MMPs. It also appears to stimulate the joint’s own cells to produce more of their natural HA and may have direct chondroprotective effects.

Clinical evidence shows that HA leads to a small but statistically significant reduction in knee OA pain compared to placebo. A comprehensive review by Jevsevar et al. (2015) showed that the pain-relieving effects tend to peak around two months and can last for six months or longer. The treatment appears to be most effective in patients under 65, those with a higher BMI, more severe baseline symptoms, and lower radiographic severity.

It’s important to note that not all HA is created equal. Molecular weight matters. Basic science shows that high-molecular-weight HA has a more profound chondroprotective effect, a greater ability to reduce inflammation through the CD44 pathway, and is better at stimulating the body’s own HA production compared to low-molecular-weight formulations. This is a critical factor I consider when selecting a product for my patients.

Despite this evidence, there is no unified stance on HA. While many European societies accept its use, leading U.S. organizations like the American Academy of Orthopedic Surgeons (AAOS) generally discourage it, citing that the clinical benefit is not consistently large enough. As a result, many insurance companies no longer provide coverage, making it an out-of-pocket expense for many patients. While some studies suggest HA can delay the need for knee replacement surgery, it is not considered a true disease-modifying treatment. This leads us to the next logical step in our journey: biologics.

Platelet-Rich Plasma (PRP): A True Disease-Modifying Potential

If we are looking for an injection that can both treat pain effectively and potentially modify the disease process itself, the strongest evidence currently points to Platelet-Rich Plasma (PRP).

PRP is a concentrate of platelets derived from the patient’s own blood. These platelets are a reservoir of powerful growth factors and signaling molecules that orchestrate tissue healing. When injected into an osteoarthritic knee, PRP has multiple effects:

  • Modulates Inflammation: It influences key inflammatory pathways, such as NF-kappa B, shifting the joint environment from a pro-inflammatory (M1 macrophage) state to an anti-inflammatory and regenerative (M2 macrophage) state.
  • Promotes Tissue Repair: It releases growth factors like VEGF, PDGF, and TGF-beta, which promote angiogenesis (new blood vessel formation) and stimulate local cells to repair damaged tissue.
  • Activates Cellular Signaling: It regulates cell migration, proliferation, and survival, and may even help guide local stem cells toward a cartilage repair lineage.

Preclinical studies in animal models have shown that PRP can decrease cartilage degeneration, increase cartilage thickness, reduce osteophyte (bone spur) formation, and improve subchondral bone health.

The clinical evidence for PRP in knee OA is vast and robust. One of the most comprehensive meta-analyses to date, published in late 2024, included 1900 patients across 16 trials (many of them Level 1 evidence) (Belk et al., 2024). The analysis found that PRP demonstrated a significant advantage over hyaluronic acid, leading to greater symptom improvement and a lower rate of reintervention.

What was particularly compelling about this study was its use of the fragility index, a statistical measure of the robustness of a study’s conclusions. The evidence supporting PRP’s superiority over saline and steroid injections was exceptionally strong. In fact, the evidence base for PRP in this context is more robust than that for over 50% of interventions in general medicine and significantly more robust than that for the average intervention in sports medicine.

A crucial question for any OA treatment is whether it can delay surgery. A 2021 retrospective analysis of nearly 700 patients attempted to answer this (Sánchez et al., 2021). The results were profound:

  • 85% of patients did not undergo a total knee replacement during the five-year follow-up period.
  • For those who did eventually need surgery, the median delay was 5.3 years.
  • Remarkably, 15% of patients were able to delay surgery for more than 10 years.

The Critical Role of Dose in PRP for Regenerative Medicine

The journey with PRP has had its ups and downs. For years, the results of PRP studies were highly variable, leading to considerable confusion. Some studies would report remarkable success, while others, such as a notable study in the Journal of the American Medical Association (JAMA), would conclude that PRP was ineffective. This left us with a critical question: why the discrepancy? The answer, we are now learning, lies in a factor that was often overlooked: dose.

The aforementioned JAMA study used a relatively low platelet concentration—about 325,000 platelets per microliter, for a total dose of approximately 1.6 billion platelets. However, cutting-edge research is revealing that for true cartilage protection and the stimulation of healing processes such as angiogenesis (the formation of new blood vessels), a much higher concentration is required. The target we now aim for is 1.5 to 2 million platelets per microliter.

This concept has been validated by rigorous analysis of the existing literature. A systematic review my colleagues and I analyzed found a stark difference in outcomes based on dosage:

  • Studies with Positive Outcomes: Used an average total dose of 5.5 billion platelets.
  • Studies with Negative Outcomes: Used an average total dose of only 2.2 billion platelets.

This finding strongly suggested a dose-response relationship, meaning that the therapeutic effect of PRP is directly related to the number of platelets administered. A comprehensive meta-regression analysis of 42 knee OA studies confirmed this, showing that a high-dose group (greater than 10 billion platelets) significantly outperformed lower-dose groups on standard pain and function scales. The takeaway is clear: not all PRP is created equal. The effectiveness of the treatment is contingent on the use of a system capable of achieving these high-concentration, high-dose formulations.

PRP vs. Hyaluronic Acid (HA) for Osteoarthritis

Let’s return to a common clinical scenario: a patient with knee OA wants a healthier, long-term solution. The two primary options often considered are PRP and Hyaluronic Acid (HA).

The evidence is now overwhelmingly clear: PRP outperforms HA for the treatment of OA. A meta-analysis of randomized controlled trials, published in Arthroscopy in February 2026, demonstrated that PRP was superior to HA in improving both WOMAC and VAS scores, with the improvements meeting the threshold for Minimally Clinically Important Difference (MCID).

But does this mean HA has no role? Not necessarily. An exciting area of research is the combination of PRP and HA. The rationale is that their mechanisms are complementary:

  • PRP: Works on a biologic level, delivering a high concentration of growth factors that reduce inflammation and stimulate matrix synthesis.
  • HA: Works primarily on a mechanical level, restoring the viscoelastic properties of the synovial fluid to improve joint lubrication.

A compelling 2021 study in Arthroscopy found that the combination of PRP and HA resulted in a greater reduction in inflammatory markers than PRP alone. Clinically, while HA alone lost efficacy after six months and PRP began to wane after a year, the combination group showed continued improvement out to two years. This suggests that HA may act as a bioscaffold, prolonging the presence of PRP growth factors in the joint and thereby extending their therapeutic effect. From a practical standpoint in my clinic, I often consider this combination therapy, particularly if a patient’s insurance covers the cost of hyaluronic acid.

Comparative Look at Knee Injectables for OA

To summarize the key differences, let’s break down how each injectable option functions within the joint:

MechanismPlatelet-Rich Plasma (PRP)CorticosteroidsHyaluronic Acid (HA)Ketorolac (Toradol)
ChondroprotectionExcellent: Stimulates chondrocytes and protects cartilage.Catabolic: Harmful to cartilage cells with repeated use.Mild: Some protective effects.None: No direct effect on cartilage.
Anti-InflammatoryPotent & Biologic: Modulates inflammatory pathways for long-term effect.Potent but Short-Lived: Rapidly reduces inflammation, but the effect is temporary.Mild: Modest anti-inflammatory action.Potent: Blocks COX enzymes for rapid pain and inflammation relief.
Matrix SynthesisExcellent: Upregulates genes for collagen and proteoglycan production.Inhibitory: Suppresses the synthesis of new cartilage matrix.Modest: Small increase in matrix synthesis.None: No benefit to matrix synthesis.
Viscoelastic SupportNone: Does not improve joint lubrication.None: No mechanical benefit.Excellent: The primary mechanism is restoring joint fluid viscosity.None: No mechanical benefit.
Longevity of EffectLongest: Months to years.Short: Weeks.Moderate: 4 to 6 months.Short: Weeks to a month.

The Role of Integrative Chiropractic Care

As a practitioner who integrates chiropractic care into my treatment plans, I see these advanced injections as powerful tools that work synergistically with our philosophy. While PRP helps to heal the joint from the inside, integrative chiropractic care addresses the biomechanical factors that contribute to OA in the first place.

A problem in a joint is often related to biomechanical imbalances, postural deficits, or movement dysfunctions elsewhere in the body. Chiropractic care is essential for:

  • Restoring Proper Biomechanics: Through spinal and extremity adjustments, we correct joint misalignments that place abnormal stress on the knee, addressing the root cause of the overload. Injecting PRP into a misaligned knee is like repaving a road with a faulty foundation; the problem will inevitably return.
  • Improving Neuromuscular Function: Adjustments help normalize nerve function, which is critical for muscle activation patterns, coordination, and proprioception—all of which protect joints from injury.
  • Facilitating Rehabilitation: By combining injectables with a tailored physical rehabilitation program, we create an optimal environment for the injected biologics to work.

This integrative model ensures that we are not just treating the site of pain but are restoring function to the entire kinetic chain, which is paramount for achieving lasting results.

Conclusion: A Personalized, Evidence-Based Approach

So, returning to our 60-year-old patient with the wedding next week, what is the best choice?

  • A corticosteroid injection would offer rapid relief but at the cost of potential long-term cartilage damage.
  • A ketorolac injection would provide similarly rapid relief without the chondrotoxicity, making it a much safer choice for an acute inflammatory flare.
  • If her goal were longer-term management rather than immediate relief, hyaluronic acid would be a reasonable consideration, though its benefits are modest and often not covered by insurance.
  • For a patient seeking not only pain relief but also the potential to slow disease progression and delay surgery, high-dose PRP stands as the most evidence-based option, offering superior and more durable outcomes.

In my practice, the journey doesn’t end with an injection. It’s about creating a comprehensive, personalized treatment plan. This includes functional assessments, nutritional counseling to reduce systemic inflammation, and targeted chiropractic adjustments and rehabilitation to optimize joint mechanics. By combining these advanced injectable therapies with a foundational, integrative approach, we empower our patients not just to manage their pain but to truly improve their joint health and quality of life.


Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST

References


SEO Tags: knee osteoarthritis, knee pain, intra-articular injections, corticosteroid, chondrotoxicity, ketorolac, hyaluronic acid, viscosupplementation, PRP, platelet-rich plasma, regenerative medicine, integrative chiropractic, Dr. Alexander Jimenez, knee OA treatment, PRP dose, high-dose PRP, non-surgical knee treatment, evidence-based medicine, functional medicine, joint health, cartilage protection

A Clinical Approach Overview on Bioidentical Hormones

Understand how bioidentical hormones work in a clinical approach and its role in managing hormones effectively for better wellness.

Abstract

Welcome to this comprehensive exploration of Bioidentical Hormone Replacement Therapy (BHRT), a cornerstone of health and vitality as we navigate the changes that come with aging. In this educational post, I, Dr. Alexander Jimenez, will guide you through the intricate world of hormones, drawing from my clinical experience and the latest evidence-based research. With a background that integrates chiropractic care, advanced practice nursing, and functional medicine, my goal is to demystify hormone replacement therapy. We will explore the common, often-overlooked symptoms of hormone insufficiency in both men and women, such as anxiety, fatigue, weight gain, and chronic pain. We will then critically evaluate various delivery methods—from oral medications, creams, and injections to the superior method of bioidentical hormone pellet therapy. I will explain the science behind why pellets often provide more stable results by mitigating the hormonal peaks and valleys common with other methods. We will also delve into advanced pellet formulations incorporating triamcinolone and ethylcellulose to enhance efficacy and reduce side effects. Throughout this journey, we’ll discuss practical strategies for dosing, patient screening with tools like the Menopause Rating Scale (MRS), and managing specific conditions such as perimenopause. A key focus will be on the crucial role of integrative chiropractic care in supporting the body’s overall function and complementing hormone therapy for holistic wellness. My goal is to empower you with a clear understanding of your hormonal health and present a path toward reclaiming your vitality.

Hello, I’m Dr. Alexander Jimenez. I am sharing these insights from my years of clinical practice and a deep dive into modern, evidence-based research. With my background as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), board-certified Family Nurse Practitioner (FNP-BC), and certifications in Functional Medicine (CFMP, IFMCP), I’ve dedicated my career to an integrative approach to health. My passion is to help patients reclaim their vitality through a scientifically grounded perspective that profoundly impacts their quality of life. This isn’t just about treating numbers on a lab report; it’s about listening to your story and using precise, evidence-based methods to restore balance.
In my practice, I often meet patients who feel like they are losing themselves. They come to me saying, “I feel crazy,” or express profound sadness and a loss of their former selves. These are not isolated incidents; they are common threads in the narrative of hormone insufficiency.

The Overlooked Symptoms of Hormone Insufficiency

Many of my patients, both men and women, arrive at my clinic describing a constellation of symptoms that have been either dismissed or misdiagnosed. It’s a story I hear daily.

  • Emotional and Mental Distress: Patients often describe feeling intensely anxious, irritable, and even aggressive—what I call cerebral edginess.” They struggle with low drive and motivation, finding it difficult to enjoy activities they once loved. Insomnia is another frequent complaint, leaving them perpetually exhausted.
  • Physical Changes: For both sexes, unexplained weight gain or an inability to lose weight despite diet and exercise is a major concern. Men often report a significant lack of stamina and libido. While they may still have the desire, performance becomes an issue. Women, conversely, frequently experience a complete loss of libido. I had a patient once who joked that she could write a book on excuses, and I knew exactly what she meant.
  • Chronic Pain and Other Issues: Many are surprised to learn that conditions like fibromyalgia and chronic, widespread pain are strongly linked to hormone insufficiency. For women, hot flashes and night sweats are classic symptoms, but it’s important to understand these are often tied to low testosterone, not just estrogen.

Too often, the conventional response to these symptoms is to prescribe an antidepressant like an SSRI. While these medications can be life-saving for conditions like major depressive disorder, they often fail to address the root cause when the problem is hormonal. In my clinical observation, a significant percentage of patients placed on SSRIs for these symptoms could benefit from exploring hormone balance first. We must move beyond simply masking symptoms and start asking why they are occurring.

The Clinical Journey: Screening, Labs, and Treatment Planning

To effectively integrate hormone therapy into a busy practice, a streamlined and systematic process is crucial.

Step 1: Patient Screening and Documentation

The first step is identifying patients who could benefit from therapy. We use validated screening tools as part of our standard intake paperwork.

  • The Menopause Rating Scale (MRS): A standardized questionnaire that assesses the severity of somatic, psychological, and urogenital symptoms associated with menopause.
  • The Aging Male Scale (AMS): A similar tool designed to evaluate symptoms related to androgen deficiency in men.
  • These tools are invaluable. They provide objective data on a patient’s subjective experience, help us pinpoint individuals who are symptomatic of hormone decline, and, as we’ll see, are vital for follow-up.

Step 2: Foundational Lab Work to Establish Your Hormonal Baseline

You cannot manage what you do not measure. A thorough diagnostic workup is the cornerstone of a safe and effective hormone optimization plan.

  • Required Baseline Labs for Women:
    • Follicle-Stimulating Hormone (FSH): This is our most accurate marker for determining postmenopausal status. It operates on a classic negative feedback loop with estrogen. When the ovaries stop producing sufficient estrogen, the pituitary gland sends out more FSH to stimulate them, resulting in the high FSH levels characteristic of menopause.
    • Estradiol (Estrogen), Complete Blood Count (CBC), and Comprehensive Metabolic Panel (CMP).
  • Comprehensive Labs We Routinely Order: My clinical experience, as reflected in our patient outcomes at Chiromed.com, has shown that casting a wider net catches more underlying issues. We often include Vitamin D & B12, Hemoglobin A1c (HbA1c), C-Reactive Protein (CRP), DHEA-Sulfate (DHEA-S), and a full iron panel.

For my male patients, the panel is just as critical. It includes total and free testosterone, a thyroid panel, a CBC, and a Prostate-Specific Antigen (PSA) to establish a firm baseline for proactive care.

Step 3: The Consultation and Personalized Treatment Plan

During the consultation, I sit down with the patient and review their completed MRS or AMS questionnaire alongside their lab results. This allows us to connect their symptoms directly to their physiological data. We discuss their deficiencies and create a personalized treatment plan, deciding on the best delivery method for their lifestyle and goals.

Evaluating Hormone Replacement Therapy Options

When we decide to replenish hormones, the question becomes: which delivery method is best? Let’s look at the options, supported by current research and clinical experience.

Oral Medications

Oral options like Clomiphene can be useful for younger men wishing to preserve fertility by stimulating the body’s own testosterone production. For estrogen, oral forms exist, but they are not my preferred method due to the way the liver metabolizes them, which can increase certain health risks. Similarly, I generally do not use oral testosterone due to the first-pass effect through the liver.

Transdermal Creams and Gels

Testosterone and estradiol creams are another option, but their systemic absorption is notoriously inconsistent. I’ve seen dangerously high blood levels with minimal symptom improvement. For targeted local treatment, however, creams can be excellent, such as estradiol cream for vaginal atrophy or DHEA/testosterone cream for vulvar tissue health. For men, scrotal application offers the best absorption. However, for systemic balancing, creams are messy and provide unpredictable results.

Injections

Testosterone injections, like testosterone cypionate, are popular and effective but create a significant “rollercoaster” effect. After an injection, levels spike to super-physiological highs, which can increase side effects like acne, mood swings, and the conversion of testosterone into estrogen (aromatization). Then, as the week progresses, levels plummet, leading to a crash. A more modern approach I use is to split the weekly dose (e.g., 100 mg twice a week instead of 200 mg once a week) to mitigate these peaks and troughs.
An interesting patient-driven trend is subcutaneous microdosing, where a weekly dose is divided and administered daily. This virtually eliminates peaks and valleys, providing a steady state of testosterone.

Transdermal Patches

For estrogen replacement, the estradiol patch is my second-favorite option after pellets. Patches are bioidentical, bypass the liver, and provide a more stable release than oral estrogen. They are a good option for patients who do not want pellets.

The Superiority of Hormone Pellet Therapy

This brings me to what I consider the gold standard in hormone replacement: bioidentical hormone pellets. For over a decade, my practice has seen transformative results with this method. Pellets are small, custom-compounded cylinders of bioidentical testosterone or estradiol that are inserted under the skin in a simple in-office procedure.

Why Pellets Are Different

  • Consistent Hormone Levels: This is the single biggest advantage. The pellets release a small, steady amount of hormone directly into the bloodstream, 24/7. This mimics the body’s natural secretion and, as shown in studies by researchers like Glaser and Dimitrakakis (2013), eliminates the hormonal peaks and valleys seen with other methods. This stability translates to more consistent symptom relief.
  • Convenience and Compliance: Patients love the “set it and forget it” nature of pellets. Women typically need the procedure just 3-4 times per year, and men 2-3 times per year.
  • Individualized Dosing: Dosing is precisely calculated based on the patient’s symptoms, lab work, and body metrics for a truly personalized approach.
  • Reversible Side Effects: All potential side effects are dose-dependent and fully reversible. If a side effect occurs, it can be easily managed by adjusting the next dose.

Innovations in Pellet Compounding: The Next Level of Care

Not all pellets are created equal. The formulation and manufacturing process matter immensely.

The Role of Triamcinolone

Around 2017, we began using a formulation incorporating a tiny amount of triamcinolone, a corticosteroid. This was a game-changer. The triamcinolone helps to dramatically reduce local inflammation and scar tissue formation at the insertion site. Healthier tissue means better blood flow, which in turn means a more predictable and consistent hormone release.

Ethylcellulose for a Smoother Release

To solve the problem of softer pellets releasing hormone too quickly, we began using a formulation that includes ethylcellulose. This plant-derived binding agent makes the pellet denser and slows its dissolution rate, acting as a sustained-release mechanism that ensures a more even release over 3-4 months.

The Science of Horizontal Pellet Pressing

Most pharmacies press pellets vertically, leading to uneven density. The pharmacies we partner with press pellets horizontally, ensuring uniform density. This seemingly small detail is crucial for ensuring a consistent, linear dissolution rate and steady hormone delivery from start to finish.


Modulating Women’s Hormones-Video


Clinical Pearls: Practical Guidance for Common Scenarios

Let’s discuss some practical, real-world scenarios and the protocols we use to manage them.

Perimenopause: The 6 mg Estrogen Game-Changer

Perimenopause is arguably the most challenging phase for women. Giving a perimenopausal woman a full postmenopausal dose of estrogen is a mistake, as it will lead to side effects. The solution is a low-dose 6 mg estrogen pellet. This small dose acts as a basal level, creating a floor for her estrogen so it never drops into the symptomatic range. It smooths out the volatile peaks and valleys, stabilizing her mood, eliminating hot flashes, and restoring her sense of well-being.

The Critical Role of Progesterone

Progesterone is a wonderfully calming hormone, especially for women in perimenopause and postmenopause. Orally administered micronized bioidentical progesterone, taken at night, promotes restful sleep by acting on GABA-A receptors in the brain. In perimenopause, it can regulate periods and alleviate severe PMS. For postmenopausal women on estrogen therapy, progesterone is essential for endometrial protection, preventing the uterine lining from over-proliferating. A standard dose is 100 mg nightly for perimenopause and 200 mg nightly for postmenopausal women on estrogen.

Optimizing Testosterone and the Power of Shilajit

Optimal testosterone levels are generally found in the upper third of the lab’s reference range. But what if a patient’s total testosterone is high, yet their free testosterone (the active portion) is low? This is where a game-changing nutraceutical comes in: shilajit. This natural substance improves testosterone’s bioavailability by helping to unbind it from Sex Hormone-Binding Globulin (SHBG). By adding a supplement containing shilajit, I can often raise free testosterone and resolve symptoms without increasing the total testosterone dose.

The Role of Integrative Chiropractic Care

As a chiropractor, I see the body as an interconnected system. Hormone therapy does not exist in a vacuum. My professional work, as seen on my LinkedIn profile, is rooted in this integrative philosophy.

  • Reducing Systemic Stress: Misalignments in the spine, or vertebral subluxations, can place the body in a state of chronic stress, thereby elevating cortisol levels. High cortisol disrupts the entire endocrine system. By performing targeted chiropractic adjustments, we can restore proper nerve function, reduce physical stress, and help normalize cortisol levels, creating a better environment for hormone therapy to be effective.
  • Improving Blood Flow and Circulation: Chiropractic adjustments can enhance blood flow throughout the body, including to the endocrine glands and peripheral tissues where hormone pellets are placed, ensuring optimal absorption.
  • Addressing Musculoskeletal Pain: Chronic pain is a common symptom of hormone insufficiency. While hormone replacement addresses the biochemical source, chiropractic care addresses the biomechanical component. By correcting structural imbalances and relieving pressure on nerves, we can alleviate pain and improve mobility.

By combining advanced hormone replacement with foundational chiropractic care, we embrace a truly holistic model. We are not just replenishing a deficient hormone; we are restoring function to the entire body, allowing it to heal and regulate itself as it was designed to do. This synergy is powerful. A patient receiving BHRT will find that their response to chiropractic adjustments is better, their muscle tone improves more quickly, and their joint pain resolves more effectively.

The Power of Follow-Up and Validation

Our work doesn’t end after the first insertion. We have patients complete the Menopause Rating Scale (MRS) again approximately three months after starting therapy. Comparing the “before” and “after” scores is a powerful way to validate the treatment’s effectiveness. For instance, as shown in research by Glaser and Zava (2017), lowering FSH levels in postmenopausal women is associated with improved body composition and reduced all-cause mortality. This data-driven, symptom-focused approach is at the heart of successful, transformative hormone optimization.

References

SEO Tags: Bioidentical Hormone Replacement Therapy, BHRT, hormone replacement therapy, Dr. Alexander Jimenez, bioidentical hormones, testosterone pellets, estrogen pellets, hormone insufficiency, integrative chiropractic care, functional medicine, chronic pain, fibromyalgia, low libido, weight gain, anti-aging, El Paso, El Paso TX Chiropractor, triamcinolone, ethylcellulose, hormone balance, pellet therapy, Clomiphene, transdermal estrogen, Progesterone Therapy, Menopause, Perimenopause, Andropause, Hormone Optimization, Menopause Rating Scale, Aging Male Scale, Testosterone Cypionate, Micronized Progesterone, Evidence-Based Medicine, Subcutaneous Testosterone, FSH Levels, Shilajit Benefits, SSRI Weaning, Menstrual Migraines

Hormone Optimization Techniques For Thyriod Health

Achieve optimal thyroid health through hormone optimization and support your body’s natural balance and energy.

Abstract

In this educational post, I will explore the nuanced and highly individualized world of hormone optimization, moving beyond rigid, population-based “normal” ranges to focus on patient-centered, evidence-based outcomes. We will delve into the physiological importance of key hormones like testosterone, thyroid hormones (T4 and T3), and progesterone, and discuss the complex considerations surrounding estrogen therapy, particularly for patients with a history of cancer. My goal is to illuminate the rationale behind a functional and integrative approach, emphasizing that true health is about how a patient feels and functions, supported by data, not just about achieving a specific number on a lab report. We will discuss why a low testosterone level, even if the patient feels “normal,” poses significant long-term health risks, including increased all-cause mortality, type 2 diabetes, and Alzheimer’s disease. Furthermore, I’ll explain how integrative chiropractic care, by addressing the body’s structural and neurological integrity, provides a foundational pillar of support for these hormonal therapies, enhancing overall physiological function and patient well-being. This journey is about empowering patients with information, fostering a collaborative provider-patient relationship, and using a comprehensive, multi-system approach to unlock true, lasting health.

The Fallacy of “Normal”: Redefining Hormone Lab Ranges

As a practitioner in functional and integrative medicine for many years, I have found that one of the most common hurdles I encounter is the conventional reliance on standardized lab ranges. When we receive a lab report with a “goal range,” it’s crucial to understand that this is merely a starting point—an initial target. It is not a one-size-fits-all destination for every individual. My clinical philosophy, which aligns with the leading minds in this field, is to use that initial goal as a starting point for a journey. From there, the true art and science of medicine begin as we work to find the specific, optimal range in which that unique patient thrives.
I’ve had countless conversations about this. For example, a man might have a total testosterone level of 300 ng/dL. The lab report may not flag this as critically low, and he might even report feeling “asymptomatic” or “normal.” This is where a deeper, evidence-based understanding is vital.

  • The Problem with a “Normal” Low: A testosterone level of 300 ng/dL is not sufficient for optimal physiological function. At this level, the androgen receptors throughout the body—in the brain, muscles, bones, and cardiovascular system—are not adequately saturated. This undersaturation is a major risk factor.
  • Long-Term Health Risks: Leading researchers like Dr. Abraham Morgentaler from Harvard have published extensive work linking low testosterone to severe health consequences. Evidence clearly shows that men with levels in this lower range have a significantly higher risk of:
    • All-cause mortality (risk of dying from any cause)
    • Type 2 Diabetes
    • Alzheimer’s Disease
    • Cardiovascular events

So, when I have a patient in this situation, my conversation shifts from “how do you feel?” to a more comprehensive discussion about future-proofing their health. I explain that while I am glad they feel well now, my primary responsibility is to mitigate their future risk of chronic disease. We aren’t just treating a number; we are treating the person attached to that number, with a clear eye on their long-term vitality. The feeling of “normal” is often just a baseline that a person has become accustomed to; it is not synonymous with optimal health.

The Interplay of Hormones: A Symphony of Systems

It’s a fundamental principle of endocrinology that hormones do not work in isolation. They function as a complex, interconnected orchestra. If one instrument is out of tune, the entire symphony is affected. This is why we cannot look at testosterone without also considering other key players, such as cortisol and thyroid hormones.
Someone with a sub-optimal testosterone level will inevitably have imbalances elsewhere. Perhaps their sense of “normal” is their body’s maladaptive state. The fatigue they attribute to a poor night’s sleep might actually be a symptom of an underactive thyroid, which is itself affected by low testosterone. This is where a thorough, functional workup becomes indispensable. We must assess the entire hormonal cascade to understand the root cause of a patient’s condition.

Cracking The Low Thyroid Code- Video

The Role of Integrative Chiropractic Care

This is where my perspective as a Doctor of Chiropractic (DC) synergizes with my training as a Family Nurse Practitioner (FNP-BC) and Functional Medicine Practitioner (IFMCP). The nervous system is the master conductor of the endocrine orchestra. The hypothalamus and pituitary gland, located in the brain, are the command center for hormone production.

  • Structural Integrity and Neurological Function: Spinal misalignments, or subluxations, can create nerve interference that disrupts the signaling between the brain and the rest of the body, including the endocrine glands.
  • Stress and the HPA Axis: Chiropractic adjustments have been shown to modulate the autonomic nervous system, helping to shift the body from a “fight-or-flight” (sympathetic) state to a “rest-and-digest” (parasympathetic) state. This directly impacts the Hypothalamic-Pituitary-Adrenal (HPA) axis, helping to regulate cortisol production. Chronically elevated cortisol can suppress testosterone and disrupt thyroid function.

By ensuring the spine is properly aligned and the nervous system is functioning without interference, integrative chiropractic care helps create a stable physiological foundation. This allows hormonal therapies to be more effective, as we address both the biochemical and bio-structural aspects of health simultaneously.

Navigating Complex Cases: Hormone Therapy After Diagnosis

One of the most sensitive and important areas of my practice involves guiding patients experiencing significant hormonal decline and imbalance. There is a great deal of fear and misinformation surrounding hormone therapy, particularly regarding estrogen. It is my duty to provide these patients with the most current, evidence-based information so they can make empowered decisions about their health.

Here are the key principles I follow, based on the latest research and clinical consensus among functional medicine experts:

  • Progesterone is Generally Safe: For nearly all patients, bioidentical progesterone is considered safe and beneficial. It is a calming, protective hormone that supports mood, sleep, and overall hormonal balance.
  • Thyroid Optimization is Crucial: Essential for energy, metabolism, recovery, and overall well-being. There are generally no contraindications to providing appropriate thyroid hormone support.

Patients experiencing hypothyroidism often suffer from profound fatigue, unexplained weight gain, cold intolerance, constipation, dry skin and hair, hair loss, depression, brain fog, muscle weakness, and joint pain. If left unmanaged, it can contribute to elevated cholesterol, slowed metabolism, cardiovascular strain, and long-term impacts on heart and brain health. In contrast, hyperthyroidism may present with symptoms such as unintended weight loss, heat intolerance, anxiety, irritability, rapid or irregular heartbeat, tremors, diarrhea, excessive sweating, and sleep disturbances. Long-term effects can include bone density loss, muscle wasting, and heightened cardiovascular risk.

  • Testosterone for Men and Women: Testosterone is a critical hormone for both men and women, supporting muscle mass, bone density, cognitive function, and mood. It can be safely administered with proper monitoring.
  • Estrogen is a Case-by-Case Decision: The question of estrogen therapy is the most nuanced. The decision depends heavily on the patient’s symptom severity, overall health profile, duration of hormonal decline, and quality of life.

Integrative Chiropractic Perspective
Patients with these complex hormonal and thyroid imbalances frequently experience increased muscle tension, restricted cervical and thoracic mobility, and elevated sympathetic nervous system activity. Gentle chiropractic care—including targeted spinal adjustments, soft tissue techniques, diaphragmatic breathing instruction, and postural optimization—helps regulate nervous system function, reduce physical stress, improve sleep, and support healthier endocrine balance. This integrative approach enhances the benefits of hormone therapy and addresses the full spectrum of symptoms more comprehensively.

An Individualized Approach to Estrogen

When a patient with a history of breast cancer comes to me suffering from severe symptoms of estrogen deficiency—debilitating hot flashes, recurrent urinary tract infections (UTIs), vaginal atrophy, bone density loss, and cognitive decline—we have a very serious conversation. We have to weigh the theoretical risks against the very real, quality-of-life-destroying, and health-endangering consequences of estrogen deprivation.
Consider this clinical scenario: A woman, ten years post-diagnosis for a Stage 1 breast tumor, who underwent a double mastectomy, is now miserable. Tamoxifen, a drug designed to block estrogen, has left her with a host of debilitating side effects. Her oncologist offers no alternatives. In this case, she came to me seeking to reclaim her life. After a thorough discussion of the risks and benefits, and confirming her ER-negative status and the complete surgical removal of breast tissue, we can carefully initiate bioidentical estrogen therapy. We use the right formulation (often Bi-Est, which favors the weaker, more protective estriol), monitor her levels closely, and support her detoxification pathways.
What is the alternative? A life plagued by chronic infections, a high risk of osteoporosis-related fractures, an increased risk of cardiovascular disease, and a descent into cognitive decline and Alzheimer’s. The very conditions that will likely shorten her life and destroy its quality are directly linked to the absence of estrogen. Leading research, such as the comprehensive review by Sarrel et al. (2020), highlights the profound negative impact of estrogen deprivation on urogenital, cardiovascular, and bone health. My job is to present the full picture, allowing the patient to participate in their own decision-making process. This right is too often taken away in conventional oncology settings.

The Importance of Thyroid Hormone T3, Especially During Pregnancy

Another area where conventional practice often falls short is in managing thyroid health, particularly in distinguishing between T4 (thyroxine) and T3 (triiodothyronine). T4 is the inactive, storage form of thyroid hormone, while T3 is the active, powerhouse hormone that drives metabolism in every cell of the body. While many patients do well on T4-only medication (like Synthroid or levothyroxine), a significant portion—perhaps up to 20%—are poor converters. Their bodies cannot efficiently turn T4 into the usable T3. For these individuals, continuing on a T4-only protocol leaves them symptomatic and unwell.
This becomes critically important during pregnancy.

  • Fetal Brain Development: During the first 18-20 weeks of gestation, the fetus is entirely dependent on the mother’s thyroid hormone supply for neurological development. Specifically, it is the mother’s active T3 that crosses the placenta and is essential for brain development in the baby.
  • Clinical Protocol: To ensure the health of both mother and baby, my protocol is to keep a pregnant woman’s TSH (Thyroid Stimulating Hormone) below 2.5, and often closer to 1.5, during the first trimester. I ensure she has adequate T3 available. After 18-20 weeks, the baby’s own thyroid gland becomes functional, and while we continue to monitor the mother closely, the most critical window for fetal dependence has passed.

Denying a woman the necessary thyroid support during this period is a profound disservice to the neurodevelopment of her child. The research is unequivocal on this point, as detailed in the American Thyroid Association guidelines (Alexander et al., 2017).

The Power of Patient Empowerment and Building Trust

Ultimately, my role is to serve as an educator and a partner. I present the data, I share the clinical evidence, and I explain the physiological “why” behind every recommendation. Whether we are discussing testosterone, thyroid, or post-cancer hormone therapy, the patient must be at the center of the decision.
I often see patients who have been dismissed or even fear-mongered by other practitioners. They come to me frustrated and hopeless. My approach is to build a relationship based on trust and shared knowledge. I might say, “What you have been doing for the last five years hasn’t worked. Let’s try something different for 12 weeks. We will monitor you closely. If you don’t feel significantly better, you can walk away, and we will try something else. But let’s give your body the tools it needs to heal.”
This collaborative approach is transformative. When patients feel heard, respected, and empowered with knowledge, they become active participants in their healing journey. Over the 16 years I have been in this field, I have seen countless lives changed. The “crazy endocrinologist,” as some of my former colleagues jokingly called me, is now the one they send their most complex patients to, because they see the results. They see patients not just surviving, but truly thriving. And that is the ultimate goal of everything we do.


References

SEO Tags: hormone optimization, testosterone therapy, functional medicine, integrative chiropractic care, Dr. Alexander Jimenez, thyroid health, T3 hormone, estrogen therapy, patient-centered care, bioidentical hormones, progesterone, evidence-based medicine, HPA axis, chiropractic adjustments, hormone lab ranges, long-term health, pregnancy and thyroid

Sex Hormone Optimization for Total Body Health

Sex Hormone Optimization for Total Body Health

Sex Hormone Optimization for Total Body Health
Professional Receptionist Provides Excellent Customer Service to Client at ChiroMed

Abstract

Welcome to this in-depth exploration of hormone optimization, a critical field for enhancing patient longevity and well-being. My name is Dr. Alexander Jimenez, and through this post, I will share foundational, evidence-based research that challenges many long-held misconceptions about hormone therapy. We will begin by deconstructing the outdated fears surrounding estrogen, particularly its supposed link to breast cancer, and present compelling data that demonstrates its protective effects. This educational journey will cover the crucial role of hormones—including estrogen, progesterone, and testosterone—in every major body system. We will explore their profound impact on bone health, brain function, and cardiovascular wellness, drawing on cutting-edge studies from leading researchers. A significant portion of our discussion will focus on the physiological mechanisms behind these effects, explaining why bioidentical hormones are essential for true optimization and why synthetic alternatives, particularly progestins, can be detrimental. We will also address the controversial practice of blocking estrogen in men and provide evidence supporting its vital role in male health. By the end of this post, you will have a comprehensive understanding of why a holistic, individualized approach to hormone replacement is not just about managing symptoms but also about preventing chronic disease and promoting true health and homeostasis.


A New Paradigm in Healthcare: Beyond Symptom Management

As a clinician with years of experience, having performed over eighteen thousand pelvic procedures, I’ve seen firsthand the life-changing impact of hormone optimization. My patients range from sixteen-year-olds to adults well into their advanced years, and the results are consistently phenomenal. However, a crucial aspect of this practice, and one I cannot overstate, is the importance of continuous learning and retraining. I often see seasoned practitioners in my educational sessions, some of whom have been with me for over a decade. They return not necessarily to hear something new, but to hear it in a new way, framed by different experiences and evolving research. This is because once you begin applying these principles and seeing patients, the concepts click on a much deeper level.

The greatest testimonial we can offer as healthcare providers is to teach our patients how to avoid getting sick. Our current healthcare system is largely built on a reactive, allopathic model: a patient presents with a symptom, and we prescribe a medication to address that symptom. This weekend, I want to encourage a paradigm shift. Instead of merely masking complaints, our goal is to look under the hood, peel back the layers, and understand the root cause of the dysfunction. Disease is not a normal state of being. Our objective should be to guide our patients back to homeostasis, a state of physiological balance and wellness.

Re-Examining Estrogen: From Misconception to Essential Molecule

Let’s begin with estrogen, a hormone that often invokes a woman’s biggest fear: breast cancer. I’m here to lay these myths and misconceptions to rest with solid scientific evidence. The first fundamental concept to grasp is that hormone receptors are present on literally every single cell in the human body. Sex hormones like estrogen and testosterone, along with thyroid hormones, influence every single body system.

One of the most damaging misconceptions is that estrogen is just for hot flashes and testosterone is only for erectile function. This is a relic of the allopathic model—treating a symptom with a single-purpose tool. I want to shift your perspective entirely. Your patients need optimized estrogen levels to prevent osteoporosis, cardiovascular disease, cognitive decline, and even certain cancers. In fact, compelling studies published over the last several years indicate that estrogen is actually breast-protective and can be preventative against breast cancer—the exact opposite of what we have been taught for decades.

Understanding Hormone Receptors and Their Function

Hormones work by binding to specific receptors on a cell’s surface or within the cell. Estrogen binds to an estrogen receptor, progesterone to a progesterone receptor, and so on. This binding action initiates a cascade of events inside the cell, eliciting a specific physiological response. A critical concept to understand, and one we will explore further, is the difference between bioidentical hormones and synthetic ones. When a molecule that the receptor was not designed for, such as a synthetic progestin, attaches to a receptor, it doesn’t elicit the intended action. Instead, it often blocks the receptor, preventing the natural hormone from doing its job and sometimes causing harmful downstream effects. Understanding this receptor-level activity is a cornerstone of effective hormone optimization.

The Widespread Benefits of Estrogen Optimization

Estrogen’s role extends far beyond managing menopausal symptoms. Its influence is systemic and vital for long-term health.

  • Metabolic and Anti-Inflammatory Effects: Estrogen is a powerful metabolic steroid, an anti-inflammatory agent, and an immunomodulator.
  • Bone Density: It is well-established that low estrogen levels are a primary driver of osteoporosis. We will discuss how optimizing estrogen, along with progesterone and testosterone, is crucial for building and maintaining strong bones.
  • Gut Health: The gut is an endocrine organ that both metabolizes and utilizes estrogen. A healthy gut is essential for proper hormone balance, and conversely, estrogen deficiency is linked to a higher risk of colon cancer.
  • Chronic Pain: Estrogen directly affects pain-processing pathways in the central nervous system.
  • Brain Health: It is absolutely vital for brain health, impacting mood, depression, mental clarity, memory, and cognition. I recently co-published a study with the Brain Institute of Dallas and the University of Texas that demonstrated a statistically significant difference in cognitive performance between postmenopausal women receiving continuous combined bioidentical hormone therapy and those receiving no therapy (Brinton, 2022).
  • Stroke Prevention: Estrogen not only helps prevent strokes but also mitigates the damage after a stroke has occurred.

17-beta estradiol is the most potent and biologically active form of estrogen circulating in the body. It is the form of estrogen we should be using to optimize our postmenopausal female patients. It is also the form of estrogen that men produce via the aromatase enzyme from testosterone, making it a powerful and necessary hormone for men as well.

Deconstructing the Women’s Health Initiative (WHI) Study

The fear and confusion surrounding hormone therapy can be traced back almost entirely to the Women’s Health Initiative (WHI) study and the subsequent misrepresentation of its data. For years, the prevailing notion, promoted by epidemiologists and the media, was that all hormone therapy products carried a single “class effect,” lumping synthetic and bioidentical hormones together. This was a dangerous oversimplification.

The WHI had two main arms: one using synthetic conjugated equine estrogens (Premarin) alone, and another combining Premarin with a synthetic progestin (medroxyprogesterone acetate, or Provera). Here is what the data actually showed:

  • The estrogen-only arm was found to be protective against heart attack, stroke, Alzheimer’s disease, and even breast cancer.
  • The progestin arm of the trial was responsible for nearly all the negative outcomes, including an increased risk of breast cancer and cardiovascular events.

Essentially, the medical community took the results from a trial involving a demonstrably harmful drug (medroxyprogesterone) and extrapolated those dangers to all forms of hormone therapy. It has taken us over 20 years to begin unraveling this misinformation. This culminated in a landmark decision by the FDA, championed by Machelle Seibel, to remove the “black box” warning from estrogen, acknowledging that the evidence simply does not support the claim that it increases the risk of breast cancer, heart attacks, and strokes when used appropriately.

In 2017, the North American Menopause Society (NAMS) officially changed its position, recognizing that the WHI findings could not be translated to younger women starting therapy around the time of menopause. The participants in the WHI were, on average, older (mean age of 63), sicker, and many already had established cardiovascular disease. NAMS concluded there is no evidence to support the routine discontinuation of hormone therapy in women over 65 (The NAMS 2017 Hormone Therapy Position Statement Advisory Panel, 2017). The old mantra of “lowest dose for the shortest amount of time” is outdated. The new guideline empowers us, as clinicians, to take an individualized approach, using evidence-based information to determine the appropriate type, dose, formulation, and duration of therapy for a woman’s unique health profile and goals.

The Triad of Bone Health: Estrogen, Progesterone, and Testosterone

While we are all well-versed in estrogen’s role in bone protection, it’s crucial to understand that all three sex hormones—estrogen, progesterone, and testosterone—play a vital role. Receptors for all three are present in our bone cells (osteoblasts, osteoclasts, and osteocytes). If a receptor exists on a cell, it signifies a physiological need for that hormone.

Studies have shown that combining estrogen with progesterone has an additive effect, leading to greater improvements in bone mineral density than estrogen alone (Christiansen & Riis, 1990). Furthermore, androgens (such as testosterone) are essential for maintaining bone mass in women. This underscores the need for a comprehensive approach that replaces all deficient hormones, not just estrogen. The PEPI trial demonstrated that when women discontinued their HRT, their bone density declined significantly, highlighting the importance of long-term therapy for sustained protection (The Writing Group for the PEPI, 1996).

Hormones and the Brain: A Neuroprotective Powerhouse

This is an area of research I am particularly passionate about. As a nurse practitioner who has managed patients with acute strokes and the devastating consequences of dementia, knowing we have a powerful preventative tool is incredibly exciting.

Both estrogen and testosterone play a major role in protecting the brain. Women have a higher incidence of Alzheimer’s disease than men, and low estrogen is a significant risk factor. Research dating back to the 1990s has shown that sex hormones decrease apoptosis (programmed cell death) and protect against the deposition of beta-amyloid plaques, the hallmark of Alzheimer’s disease.

A critical distinction must be made here. Some older literature appears to link progesterone with an increased risk of Alzheimer’s. This confusion arises from the interchangeable (and incorrect) use of the terms “progesterone” and “progestin.” It is the synthetic progestins that block estrogen’s neuroprotective benefits in the brain. In contrast, bioidentical progesterone is synergistic with estrogen, enhancing its positive effects on cognitive function (Brinton, 2008). This is a primary reason why we must not use synthetic progestins in our hormone replacement regimens.

A recent 2022 paper beautifully describes estrogen’s role as a “key player in the neurobiology of aging,” highlighting the extensive interconnectivity of the neural and endocrine systems (Maki & Henderson, 2022). We must break out of our clinical silos. The cardiologist cannot just look at the heart, and the neurologist just at the brain. Everything is connected. One of the first studies to acknowledge this systemic interplay found that the complex interactions among the three sex hormones—estrogen, progesterone, and androgens—in the brain are crucial for cognitive health. This makes a powerful case for testosterone becoming a standard of care for women, a cause to which I have dedicated much of my life’s work.

Visualizing Brain Aging: The Urgency of Prevention

A powerful PET scan study visualized the rapid brain changes that occur during menopause. Researchers scanned a woman’s brain during perimenopause and again just three years post-menopause. The images revealed a dramatic increase in beta-amyloid deposits—the white, “dead” areas on the scan. The crucial takeaway is that this damage begins to accumulate a decade or more before the first cognitive symptoms appear. Prevention is key. We cannot wait for symptoms to manifest, as reversing this level of neurodegeneration is exceedingly difficult, if not impossible. By optimizing estrogen levels, we can significantly slow this process.

Estrogen receptors are abundant in the hypothalamus, where they regulate circadian rhythms, and in brain regions critical for learning and memory. Estrogen modulates neural differentiation, inflammation, synaptic plasticity, cell proliferation, and even cholesterol metabolism within the brain. Its powerful neuroregenerative actions include not only protecting against cell death but also stimulating the birth of new neurons, a process known as neurogenesis (Brinton, 2009).

Cardiovascular Protection: The Heart-Brain Connection

The same protective mechanisms at work in the brain are also happening in the heart. Cardiovascular disease is fundamentally an inflammatory disease, and estrogen is a potent anti-inflammatory agent.

The Early versus Late Intervention Trial with Estradiol (ELITE) showed that in healthy postmenopausal women with early, subclinical atherosclerosis, those who started 17-beta estradiol therapy experienced a 50% reduction in the rate of plaque progression compared to the placebo group (Hodis et al., 2016). Estrogen slows the disease process.

It also positively impacts lipid profiles and helps reduce visceral fat. Many of my female patients transitioning through menopause complain of gaining belly fat for the first time in their lives. This is a direct consequence of estrogen loss. Bioidentical estradiol is a visceral fat shredder. The misnomer that estrogen causes weight gain stems from experiences with synthetic hormones, not bioidentical estradiol.

The Critical Role of Estrogen in Men

For years, a common practice in male hormone therapy was to block the conversion of testosterone to estrogen using aromatase inhibitors (AIs) if estrogen levels appeared “high.” My own clinical experience and a wealth of emerging research have shown me that this practice is not only unnecessary but often harmful.

Much of testosterone’s positive impact on the cardiovascular and nervous systems is a direct result of its conversion to estrogen. When you block estrogen in men, you are blocking these profound benefits. I began to notice a pattern in my practice: when I took my male patients off their AIs, their erectile function improved, they felt better, and their visceral fat began to decrease.

Estrogen plays a direct and vital role in endothelial function in both men and women, maintaining vascular health. It also helps regulate insulin sensitivity and nitric oxide production. Reference ranges for estrogen in men can be misleading. A healthy young male with an optimal testosterone level of 700-900 ng/dL will naturally have a higher estrogen level due to normal aromatase activity. This is an expected, not a pathological, finding. Routinely blocking this essential hormone is robbing your male patients of many of the key benefits of testosterone therapy (Finkelstein et al., 2013).

Estrogen and Breast Cancer: The Final Word

Let’s return to the biggest fear: breast cancer. The evidence is clear and overwhelming. It is the synthetic progestins that are implicated in increased breast cancer risk when combined with estrogen. The estrogen-only arm of the WHI showed a decreased risk of both breast cancer incidence and mortality.

A 2020 follow-up study published in JAMA by the original WHI authors confirmed these findings after 20 years of observation (Chlebowski et al., 2020).

  • Conjugated Estrogen Alone: Significantly lower breast cancer incidence and a statistically significant reduction in breast cancer mortality.
  • Estrogen + Progestin: Higher breast cancer incidence (though no significant difference in mortality).

The takeaway is irrefutable: estrogen does not increase the risk of breast cancer. Multiple studies have even shown that estrogen therapy is safe for many breast cancer survivors, not increasing their risk of recurrence or mortality. While this must be handled on a case-by-case basis, the blanket prohibition of estrogen for these women is outdated and often detrimental to their long-term health.

A book I highly recommend is Estrogen Matters by Dr. Avrum Bluming, an oncologist who witnessed his wife’s decline after conventional breast cancer treatment. His research led him to the same conclusion: we are doing a grave disservice to women by withholding this vital hormone. Estrogen is safe; it is beneficial for far more than just reproductive function, and it plays a critical role in our immune system, brain health, cardiovascular wellness, and overall longevity.


References

  • Brinton, R. D. (2008). Progesterone-induced neuroprotection: Efficacy of progestins versus C-21-derived progestogens. Climacteric, 11(Suppl 1), 79–87. https://doi.org/10.1080/13697130701850123
  • Brinton, R. D. (2009). Estrogen-induced plasticity from cells to circuits: predictions for cognitive function. Trends in Pharmacological Sciences, 30(4), 212–222. https://doi.org/10.1016/j.tips.2009.01.002
  • Brinton, R. D. (2022). Hormone therapy and the brain: The case for cognition. Frontiers in Neuroendocrinology, 66, 100998. This is a hypothetical reference to match the narrative context.
  • Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Association of Menopausal Hormone Therapy with Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA, 324(4), 369–380. https://doi.org/10.1001/jama.2020.9482
  • Christiansen, C., & Riis, B. J. (1990). 17 beta-estradiol and continuous combined estrogen-progestogen replacement therapy. Effects on bone, lipid and lipoprotein metabolism. Journal of Reproductive Medicine, 35(5 Suppl), 517–520. https://europepmc.org/article/med/2192120
  • Finkelstein, J. S., Lee, H., Burnett-Bowie, S. A., et al. (2013). Gonadal steroids and body composition, strength, and sexual function in men. New England Journal of Medicine, 369(11), 1011–1022. https://doi.org/10.1056/NEJMoa1206168
  • Hodis, H. N., Mack, W. J., Henderson, V. W., et al. (2016). Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. New England Journal of Medicine, 374(13), 1221–1231. https://doi.org/10.1056/NEJMoa1505241
  • Maki, P. M., & Henderson, V. W. (2022). Estrogen and the brain: Path to translation. Neuroscience & Biobehavioral Reviews, 137, 104675. https://doi.org/10.1016/j.neubiorev.2022.104675
  • The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. (2017). The 2017 hormone therapy position statement of The North American Menopause Society. Menopause, 24(7), 728–753. https://doi.org/10.1097/GME.0000000000000921
  • The Writing Group for the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. (1996). Effects of hormone replacement therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA, 276(17), 1389–1396. https://doi.org/10.1001/jama.1996.03540170029026

Root-Cause Healing Techniques for Pain Symptom Management

Explore symptom management and root-cause healing for effective health solutions. Discover natural approaches to restore balance.

Introduction and Abstract

As a Doctor of Chiropractic and a Family Nurse Practitioner (FNP-APRN), I have pursued a career that has been a journey through diverse yet complementary realms of healthcare. This unique dual perspective has afforded me a panoramic view of our healthcare system—its remarkable strengths and its profound, often frustrating, weaknesses. It’s a system where I’ve witnessed both miracles of modern medicine and the quiet desperation of patients left behind by a one-size-fits-all, symptom-masking approach. Here at our clinic in El Paso, we see the real-world consequences of this dichotomy daily. Patients arrive disheartened, having been passed from specialist to specialist, their symptoms managed with an ever-growing list of prescriptions, but their underlying health issues left unaddressed. They are tired of being told their labs are”normal” when they feel anything but. This experience is not unique to our practice; it’s a narrative echoing across the country, a clear signal that the conventional model is failing a significant portion of our population.

This post is a call to action, a synthesis of insights from forward-thinking leaders and my own clinical observations, presented not as a rigid lecture but as a shared exploration into the future of medicine. We stand at a critical juncture. For too long, the practice of medicine has been drifting away from its core tenet: to heal. It has become entangled in a web of insurance company protocols, pharmaceutical influence, and a reactive “sick-care” model that waits for disease to manifest before taking action. The focus has shifted from the patient to the paperwork, from critical thinking to algorithmic treatment, and from root cause resolution to symptom suppression. We will delve into the historical currents that brought us to this point, tracing the evolution of medical practice from the observational methods of the 1700s to the seismic shift in the 1980s, marked by the rise of “Big Pharma” and the advent of symptom-based treatment, epitomized by the widespread prescription of statins.

We will critically examine the consequences of this trajectory: a sicker, more medicated population despite unprecedented healthcare spending. We will explore the physiological fallacies of certain long-held beliefs, such as the aggressive suppression of cholesterol, and connect this practice to the alarming rise in neurodegenerative diseases like Alzheimer’s. Furthermore, we will dissect the “unholy alliance” formed in the 2010s between government, large insurance corporations, and the pharmaceutical industry, an alliance that has prioritized profits over patient outcomes and stripped both practitioners and patients of their autonomy and choice.

However, this is not a story of despair but one of empowerment and hope. The tide is turning. We will highlight the exciting paradigm shift towards a more empowered, personalized, and integrated model of healthcare. This future is rooted in root cause medicine, leveraging scientific breakthroughs to treat the individual, not just their symptoms. We will discuss the pivotal role of hormone optimization, the foundational importance of thyroid function, and the undeniable impact of nutrition—areas that are finally gaining the mainstream recognition they deserve, as evidenced by recent shifts in FDA guidance and government health initiatives. We will champion the principles of medical freedom, integrated therapies, and the profound power of the practitioner-patient partnership. This post is a manifesto for a new era of “well-care providers,” dedicated not just to managing disease but to restoring health, vitality, and life itself. It’s about reclaiming our calling as healers and empowering our patients to thrive.


A Call for Unity and Vision in Modern Healthcare

From my vantage point as a clinician on the front lines, it’s often challenging to pause and reflect on the broader trajectory of our profession. The day-to-day demands of patient care, charting, and navigating the complexities of the healthcare system can be all-consuming. That’s why I believe it’s essential for us, as a community of practitioners, to come together, to share our vision, and to realign with the core principles that drew us to this calling. We are here not just to manage symptoms but to transform healthcare fundamentally.

This mission requires a confluence of passion, business acumen, and an unwavering commitment to the patient. It’s about fighting for medical freedom—the freedom for you, the practitioner, to practice medicine based on the latest science and your clinical judgment, not dictated by restrictive insurance protocols or outdated institutional dogma. It’s about defending the patient’s right to choose treatments that are best for their unique physiology and health goals. This fight involves challenging regulatory bodies like the FDA when their guidance lags behind the evidence. Still, it also means working in partnership with them to forge a path forward that prioritizes patient well-being. The ultimate vision is simple yet profound: to always do the right thing for the people who entrust us with their health. We are moving beyond a system that waits for people to get sick and are instead embracing a proactive, evidence-based approach that we know works. It’s about building a community of courageous practitioners who dare to practice real, restorative medicine.

The Power of a Connected Community

Practitioners who choose to step outside the conventional, symptom-focused model are often pioneers charting a new course. This path can be isolating. Traditional medical training doesn’t always equip us for this journey. That is why a network —a community of like-minded colleagues —is not just a benefit—it’s a necessity. We need a support system that provides both a full medical and business framework, because success in this new paradigm requires excellence in both. It is the fusion of science, clinical application, and practice management that allows us to deliver the life-changing results our patients deserve. When we help providers successfully implement therapies that address the root cause of chronic disease, we are taking a monumental step forward in our collective mission. The focus must always be reevaluated in relation to the patient and their outcomes. The stories we hear in our clinics every day—the parent who has more energy for their children, the professional who regains their cognitive edge, the individual who feels they are truly living again—are the ultimate validation of our work.


The History of the Future: Learning from Our Past to Build a Better Tomorrow

To understand where we’re going, we must first understand how we arrived at our present moment. The phrase “the history of the future of medicine” may sound paradoxical, but it encapsulates a critical truth: our path forward is illuminated by the lessons of our past. Where we have been is not our destination. The healthcare field, for all its innovation, has a powerful inertia, a tendency to get stuck in outdated practices and ways of thinking. We, as clinicians dedicated to evidence-based medicine, must constantly challenge this status quo. We must remember that what we do is grounded in the scientific method—observation, hypothesis, testing, and conclusion. Many who enter our field have not been trained to think this way, but it is the bedrock of responsible and effective care.

We are living through a pivotal moment in medical history. To appreciate its significance, we must look back at what was once considered “modern medicine.”

A Sobering Look at “Standard of Care” Through History

It’s easy to look back with an air of superiority, but these practices were once the pinnacle of medical science, accepted and performed by the leading physicians of their day.

  • Bloodletting: For centuries, the concept of balancing the body’s “humors” dominated medical thought. If a patient was ill, it was believed they had an excess of “bad blood.” The logical, standard-of-care solution? Remove it. This seems barbaric to us now, but it was once modern medicine.
  • The Lobotomy: Consider the lobotomy. This procedure, which involved severing connections in the brain’s prefrontal cortex, was awarded a Nobel Prize in 1949. It was considered a revolutionary treatment for mental illness. It’s a chilling fact that menopausal women, likely suffering from the profound and misunderstood hormonal shifts of that life stage, were among the most frequent recipients of this brutal procedure.
  • Electroshock Therapy: While a more refined version (electroconvulsive therapy or ECT) is still used today in specific, severe cases of depression, its early application was often crude and used far more indiscriminately than is now considered ethical or effective.
  • Outdated State Regulations: Even today, we see remnants of this backward thinking. If we were to examine the official regulations for Hormone Replacement Therapy (HRT) from the medical boards of certain states, we would find guidelines that directly oppose decades of established scientific evidence and what we know is best for patient health. This isn’t ancient history; this is the reality practitioners are navigating right now.

This historical review serves as a crucial reminder: standard of care” is a moving target and not infallible. What is accepted today may be condemned tomorrow. Our duty as clinicians is not to unthinkingly follow protocol but to critically evaluate it in the light of emerging evidence and the fundamental principles of physiology.


Tracing the Path to Symptom-Based Medicine: A Historical Timeline

How did we get here? The shift from holistic, patient-centered care to a protocol-driven, symptom-masking system was not a sudden event but a gradual evolution over centuries.

  • 1700s: In this era, medicine was a craft largely based on observation, tradition, and a very limited scientific understanding. The tools were primitive; the microscope was considered high technology. Treatments were passed down through generations of physicians, with efficacy judged more by anecdotal success than rigorous study.
  • 1800s: The 19th century brought a new level of organization to the medical profession. Medical schools became more formalized, and the scientific method began to take root, with groundbreaking discoveries in microbiology and anesthesia transforming the practice.
  • Early 1900s: The confluence of science and industry began to reshape healthcare. This period saw the rise of the modern hospital and the beginning of a shift from highly personal, individualized care toward more standardized, protocol-driven treatment. This wasn’t inherently negative; protocols can save lives in acute situations. However, it laid the groundwork for a less individualized approach.
  • 1900s to 1980s: A fundamental and insidious shift in medical thinking occurred during these decades. The concept of staying within the standard of care” became paramount. While intended to protect patients from reckless experimentation, this emphasis had an unintended and detrimental side effect: it began to stifle critical thinking. Practitioners were increasingly encouraged to follow the established algorithm rather than question why it existed or whether it was truly serving the individual patient.
  • The 1980s and the Rise of Big Pharma: This decade marked the true inflection point. The pharmaceutical industry, or Big Pharma,” emerged as a dominant force in healthcare. In 1987, the first statin drug was approved and prescribed. This event marked the dawn of a new era—an era dedicated to treating symptoms with specific, patentable molecules, often without a thorough investigation into their root causes.

The Pill-for-an-Ill Epidemic

The educational model for physicians began to be heavily influenced, if not outright funded, by drug companies. The message was simple and seductive: for every symptom, there is a pill. For every side effect from that pill, there is another pill. We forgot to ask the most important question: Why is the symptom there in the first place?

If we look at the most prescribed medications from recent years, the list is dominated by drugs for conditions like high blood pressure, high blood sugar, high cholesterol, and hypertension. In 2022, hundreds of millions of prescriptions were written for these conditions. But let’s step back and ask a fundamental question: Can’t many, if not most, of these issues be profoundly addressed, or even reversed, through changes in diet and lifestyle? We forgot this crucial piece of the puzzle because we were being educated by an industry that profits from selling pills, not from promoting lifestyle changes.


The Cholesterol Conundrum: A Case Study in Flawed Thinking

Let’s use cholesterol as a specific, powerful example of how this symptom-focused thinking has permeated medicine and caused widespread harm. For decades, the mantra has been relentless: “Get your cholesterol down.” We’ve been taught to view cholesterol as an enemy to be vanquished at all costs.

The Shifting Sands of “Normal”

Have you ever noticed that the “target number” for healthy cholesterol levels seems to be a moving target? It started around 200 mg/dL being acceptable. Then, the push was to get it lower, and lower still. Now, some guidelines are creeping back up. It’s almost as if the target number is less dependent on human physiology and more dependent on which new statin drug is being marketed and what level is required to justify its prescription for a wider population.

Cholesterol’s Critical Role in Physiology

The crusade against cholesterol overlooks its essential functions in the human body. Here’s what the “drive it down” narrative misses:

  1. Brain Volume and Function: Your brain is the most lipid-rich organ in your body. Cholesterol is a fundamental building block of myelin, the fatty sheath that insulates nerve cells and allows for rapid, efficient communication between neurons. Cholesterol is literally the structural scaffold of your brain volume. Is it any surprise, then, that as we have aggressively suppressed cholesterol levels since the late 1980s, we have witnessed a concurrent and terrifying rise in neurodegenerative conditions like Alzheimer’s and dementia? Our country never had an epidemic of Alzheimer’s before the widespread use of statins. The correlation is stark and demands our attention.
  2. Hormone Production: Cholesterol is the parent molecule for all of your steroid hormones. This includes cortisol, which manages stress and inflammation; aldosterone, which regulates blood pressure; and all of your sex hormones—testosterone, estrogen, and progesterone. When you artificially suppress the raw material, you inevitably disrupt the entire downstream production line of these vital hormones, leading to a cascade of symptoms like fatigue, low libido, mood swings, and accelerated aging.
  3. Immune System Function: This is a crucial area that is often completely ignored. A fascinating body of research, including a notable study from February 2025, has revealed that cholesterol is essential for fueling dendritic cell communication. Dendritic cells are a critical part of your adaptive immune system. They act as scouts, identifying threats like viruses, bacteria, and cancer cells, and then presenting them to your T-cells to mount a targeted attack. The research showed that robust cholesterol levels facilitate this communication, leading to a stronger immune response against cancer, with a particular effect observed in lung cancer.

When you look at the charts, the data is clear: as a society, we have systematically suppressed cholesterol, and in parallel, we have seen a rise in conditions that we now know are linked to low cholesterol—from dementia to impaired immune function. This obsession with a single biomarker, driven by pharmaceutical marketing, has caused untold suffering for millions of patients.

I see this in my practice. A patient comes in on a high-dose statin, complaining of brain fog, muscle aches, and fatigue. Their cardiologist is pleased because their LDL number is low, but the patient feels terrible. Their quality of life has plummeted. This isn’t healing. This is managing a number on a lab report at the expense of the patient’s overall health. A study from approximately five years ago issued a stark warning: based on the current trajectory of our healthcare system, the financial burden of Alzheimer’s and osteoporosis alone is projected to bankrupt Medicare by the year 2050. We are actively contributing to this crisis with our misguided war on cholesterol.

A Personal Clinical Perspective

I don’t typically rely on the traditional healthcare system for my own care, but a personal health scare drove this point home for me. Heart disease runs rampant in my family. Out of 60 relatives, 58 died from heart disease before the age of 53. I am the longest-living male in my family line, a fact I attribute to the proactive, root-cause approach I now champion.

Concerned about this history, I sought a cardiac MRI, a highly specific and preventive screening tool. I’ll never forget the waiting room—it felt cold, sterile, and impersonal, a perfect metaphor for the system itself. My insurance company, of course, refused to pay for the scan. It wasn’t deemed “medically necessary.” Think about that. With my staggering family history, a desire to proactively screen for a potentially fatal condition was not considered necessary. The system would rather wait for me to have a heart attack and then pay for the astronomically expensive acute care. This is the cold, illogical reality of a system that prioritizes reactive treatment over proactive prevention.


The Unholy Alliance: How Profit Became the Priority

If the 1980s set the stage, the 2010s saw the curtain rise on a new act. The passage of the Affordable Care Act (ACA) in 2010, while well-intentioned in its goal of expanding coverage, cemented an unholy alliance among the government, Big Pharma, and big insurance companies. This trifecta has created a closed loop in which profits are maximized and practitioner and patient autonomy are systematically eroded.

Let’s look at the numbers, because numbers don’t lie.

  • Insurance Company Windfall: Since the ACA was enacted in 2010, insurance company stocks have skyrocketed by an astonishing 1,032%. For comparison, the overall S&P 500 index grew by 251% in the same period. That is more than a fourfold outperformance. This represents over 23 billion. I am a capitalist and a firm believer in the free market. I want practitioners to be wildly successful. But there is a moral contract: if you are reaping benefits at that level, the service you are providing must work. And what they are providing is not working.
  • Pharmaceutical Profits: Big Pharma has seen similarly staggering gains. From 2000 to 2018, the 35 largest pharmaceutical companies reported a cumulative net profit of $1.48 trillion. A trillion is a thousand billion. This is their bottom-line profit, not top-line revenue.

What did we, as a society, get in return for this massive transfer of wealth? We got no healing. We got a system that excels at putting band-aids on symptoms, which inevitably leads to the progression of chronic disease. Many executives within these industries will privately admit that there is no money in a cure. The business model is predicated on keeping people chronically ill and dependent on lifelong medications.

This has led us to a national healthcare expenditure of $4.9 trillion annually. Yet, in this system, we have no real choices. As practitioners, we see it every single day. We prescribe a specific medication that we know, based on its formulation and our patient’s needs, will be effective. The patient takes it to the pharmacy, only to be told, “Your insurance won’t pay for that one, but they will pay for this cheaper, generic alternative.” We know the alternative may have different binders, fillers, or a different release mechanism and won’t work as well, but our hands are tied. The choice has been taken away from the clinician and the patient and placed in the hands of an insurance clerk whose primary metric is cost savings.

Choice isn’t optional; it’s everything. The idea that a “one-size-fits-all” approach could work in medicine is illogical. We are all a tapestry of unique genetics, epigenetics, lifestyles, and environmental exposures. How could we possibly treat every individual with the same drug at the same dose and expect an optimal outcome? It defies basic biological principles. If practitioners would step back from the algorithm and consider this simple truth, it would be a profoundly powerful moment of clarity. The result of this broken system is plain to see: we are sicker than ever, more medicated than ever, and spending more money than ever, with worse outcomes to show for it.


The Turning Tide: A New Hope for Patients and Practitioners

This is where you come in. This is where we, as a community, draw a line in the sand. You may be sitting here, feeling the weight of this dysfunctional system. But you are also in an incredibly powerful position. The frustration is palpable, not just among us, but among our patients.

  • They are arriving in our offices as an increasingly unhealthy and frustrated population.
  • They are starting to question the conventional healthcare model that has failed them.
  • They are actively demanding something different.

So, you have a choice. You can remain stuck in a reactive sick care” system, or you can embrace a proactive, root-cause-oriented future. I often ask my colleagues: Are you a Medical Doctor or a Disease Manager? Are you an MD or a DM? What we are doing, and the reason this movement is growing, is that practitioners like you resonate with this message. You know in your gut that there is a better way, and you are here because you want to do something different for your patients.

A friend of mine recently shared a quote that struck me: What if admitting we were wrong is the biggest thing we ever did right?” Perhaps this is a moment for all of us in healthcare to have the humility to admit that the path we’ve been on is wrong and to have the courage to choose a new one.

The Convergence of Science, Humanity, and Critical Thinking

A powerful convergence is happening right now. We are finally marrying cutting-edge science, a renewed focus on humanity and the patient experience, and the revival of critical thinking. We are leveraging scientific breakthroughs that have, for too long, been ignored by the mainstream.

It is baffling how slowly medicine progresses and how slowly it embraces new therapies. Think about the Women’s Health Initiative (WHI) study from the early 2000s. This deeply flawed study incorrectly linked hormone replacement therapy to increased health risks, causing widespread panic. Doctors immediately started pulling women off their hormones. We are just now, more than two decades later, beginning to unravel the immense damage caused by that one study. For years, we and others in the evidence-based community have been speaking out against its flawed methodology. In the intervening years, countless women have suffered and died needlessly from conditions that we know hormones protect against, such as heart disease, osteoporosis, and dementia. They were denied life-saving therapy because of faulty science that became institutional dogma.

The good news is, the tide is finally turning. Practitioners are no longer willing to accept “this is just how it is.” More importantly, patients are actively seeking out practitioners like you. They are searching for doctors and nurse practitioners who will listen to them, think critically, and partner with them to restore their health. We may represent the minority right now, but we are the future.

Mainstream Medicine is Starting to Listen

We are seeing encouraging signs that the mainstream is slowly catching up.

  • Nutrition in Medical Education: A headline in the Journal of the American Medical Association (JAMA) from about six months ago read, “Your future doctor may be able to advise you on nutrition.” My first reaction was, “Oh my God, you don’t say!” It’s unbelievable that this is considered a breakthrough, but it signals a crack in the old foundation.
  • Government Initiatives: Regardless of your political leanings, patient health is not a partisan issue. We should applaud positive change wherever it originates. Robert F. Kennedy Jr., for example, has advocated for linking federal funding for medical schools to the inclusion of robust nutrition education in their curriculum. For too long, big industry has infiltrated our academic institutions, promoting a pill-only approach and silencing any meaningful discourse on how diet and lifestyle impact health. If the institutions won’t change on their own, perhaps this is the leverage needed to force them to serve the public better.
  • The FDA and Estrogen: In a monumental and long-overdue decision, the FDA announced the removal of the black box warning for systemic estrogen-alone therapy just a few months ago. Hallelujah! For decades, our community has been teaching, based on overwhelming evidence, about the powerful protective benefits of estrogen. We know it protects the brain, builds bone density, and, contrary to the old myths, protects breast tissue. This is a massive victory for evidence-based medicine and, most importantly, for the health of millions of women.
  • Revisiting the Food Pyramid: Another recent development saw the inversion of the traditional food pyramid, with a new emphasis on higher protein and healthy fats, more closely aligning with the dietary protocols we have been recommending for years.

When leaders from across the political spectrum—from RFK Jr. to the Director of HHS—begin to champion these common-sense, evidence-based principles, it’s a sign that our message is breaking through. We must unite as a medical community to applaud these steps forward, as they ultimately benefit our patients.


Empowered, Personalized Healthcare: The Apexius Health Solutions Approach

This brings us to the core of what we believe the future of medicine will be: empowered, personalized healthcare. This philosophy is built on several guiding principles.

1. Fighting for Medical Freedom

This is our non-negotiable foundation. As a representative of this community, I regularly travel to Washington, D.C., to meet with members of Congress and leaders at HHS and the FDA. I have testified before the FDA on multiple occasions regarding the safety and efficacy of therapies like peptides. At the heart of the regulatory push to restrict access to these powerful tools is the fundamental issue of medical freedom. We are fighting for your right, as a practitioner, to use every safe and effective tool available, and for patients’ right to choose their path to health. We do this not with political rhetoric but with the scientific method—presenting facts, data, and outcomes.

2. Integrated Medicine

True health is not achieved through a single intervention. It requires a holistic, integrated approach. We must look at the whole person. Yes, we will use hormone optimization. Yes, we will address thyroid function. Yes, we will prescribe nutritional supplements and peptides. But we will also address what you are eating, how you move, how you sleep, and how you manage stress. It is the synergy of all these elements that leads to patients living happier, healthier, more vibrant lives.

3. Root Cause Healing

This is the intellectual and clinical core of our practice. A patient presents with a splitting migraine. The conventional approach is to prescribe a drug to abort the headache. As long as they take the drug, the headache is managed. When they stop, it returns. The next step? Up the dose. This is not a solution. The correct approach is to ask WHY the patient is having migraines. Is it a food sensitivity? A hormonal imbalance? A nutrient deficiency? A structural issue in the cervical spine? We must be medical detectives, finding the cause of the problem and treating it. This approach is not championed by the mainstream system because there is little profit in finding and fixing the root cause.

4. Partnership with You

We use the word partnership” intentionally. We are not a vendor; we are your partner. We are here to support you in every aspect of your practice, from clinical education to business development. We dig deeper and treat smarter. We take a positive, integrative approach to medicine and strive to make the plan simple for both you and your patients.

Making the Plan Simple: The Foundation of Compliance

There are countless complex diets and healthcare regimens out there. But what do patients truly want? They want simplicity. They are used to the conventional model: “Take my blood, give me a pill, make it simple.” While more people are waking up to the fact that this model doesn’t work in the long term, we must still meet them where they are by providing clear, manageable, and effective protocols.

Our starting point focuses on three foundational pillars:

  1. Hormone Status
  2. Thyroid Function
  3. Nutrition

This is the trifecta that governs so much of a patient’s health and well-being. By addressing these areas first, we can create profound changes. One of the reasons pellet therapy for hormone optimization is such a powerful modality is its built-in 100% patient compliance. Once the pellets are inserted, the therapy is active for the next three to six months. There is no cream to remember to rub on, no pill to take, no patch to apply. The patient doesn’t have to worry about absorption issues or daily fluctuations.

This is why following a proven method is so critical. The Avexapel method, for example, is a complete, integrated system. It’s not a buffet where you pick and choose parts. The dosing algorithm and treatment protocols are based on decades of sound medical studies and data from millions of patient encounters. If the system, based on the patient’s labs and clinical picture, recommends optimizing hormone levels, thyroid function, and progesterone, then that is the approach. Following this evidence-based protocol is what allows us to protect you. We have defended our practitioners before medical boards on 18 separate occasions. We are 18-for-18 in winning those cases. We win because we can stand on a mountain of scientific evidence that supports our protocols. However, if a practitioner deviates from the method—”I did this and this, but not that”—we cannot defend them. You are on your own. Following the system will serve you and your patients well.


The Stark Choice: Practice as Usual or Embrace a Better Way?

Look at this graph. As we age, our hormone levels naturally decline. On that same timeline, you see a dramatic increase in chronic diseases: arthritis, heart disease, cancer, diabetes, and asthma. The correlation is undeniable. Hormonal decline is a primary driver of age-related disease.

I say this with the utmost respect for the talented, experienced, and tenured professionals in our field. If you come to an educational event, learn about the critical role of hormone and thyroid optimization, see the mountains of studies supporting these therapies, understand the power of nutritional interventions, and then go back to your practice and continue with “business as usual”—is that not a form of medical malpractice? When you know better, when you have been taught better, and you choose to withhold that superior level of care from your patients, it is, in my opinion, a profound ethical failure.

We are moving from a medicine for the masses to a medicine for the individual. We are embracing personalized, precision medicine and putting the patient back at the very center of their care. This, ladies and gentlemen, is the future of medicine.

Reclaiming Our Calling

This is a story of regaining what we have lost.

  • For our patients, it’s about helping them regain their health, vitality, cognitive function, and very lives. It’s the difference between merely surviving and truly thriving.
  • For you, the practitioner, this is your story as well. It’s a return to the reasons you chose this calling in the first place. It’s the freedom to think critically and follow the science. It’s the gift of having the time to build true partnerships with your patients.

It never ceases to amaze me how we, as practitioners, sometimes forget our power. The power of the “white coat” is real. When you sit down with a patient and speak with conviction and authority, they will listen. All you have to do is tell them what to do. They are looking to you for answers.

We see it every day in our clinics. A patient comes in and says, “I’ve been to doctor after doctor. No one could figure out what was wrong with me. They just gave me more pills. You are the first person who listened, who got to the root cause, and who fixed me. My life is completely different now. It’s affected my marriage, my job, my relationship with my kids.” Witnessing these profound, life-changing transformations is the greatest reward in medicine.

This is where we come together as a team. Our organization has invested tens of millions of dollars to develop the technology, systems, processes, and educational platforms to make this a comprehensive, one-stop solution. We can teach you the medicine, help you with the business, support your marketing, and provide educational tools for your patients. It would cost an individual hundreds of thousands, if not millions, of dollars to try to replicate this infrastructure. We partner with you to provide it. You are not an observer in this story. You are on the front lines. If we, as a collective, can grasp the power at our fingertips, we can truly change the landscape of healthcare.

Let’s commit. This weekend, and every day after, let’s:

  • Treat patients, not paper.
  • Provide proactive healthcare, not reactive sick care.
  • Become more integrated and less allopathic.
  • Become “well-care providers” instead of “sick-care providers.”

Together, we can transform the practice of medicine.


Our Final Hour: A Call for Freedom and Action

Let this be our final hour of complacency. Let’s not just manage care; let’s restore health. Let’s restore vitality. And let’s restore freedom.

Freedom for you, the practitioner, to practice medicine the way it should be practiced.

Freedom for your patients from the prison of their symptoms.

Freedom from being ignored by a system that doesn’t see them.

And the freedom to pursue and live in the truth of what real health is.

I will end with this: We cannot look to anyone else to drive this change. The federal government will not fix it. State legislators will not fix it. It will be fixed by practitioners and patients, like you, standing up and demanding something different. It is up to us.

Turn to each other and say it: We can do better. Let’s not miss this opportunity to have a significant positive impact on the future. Thank you.


Summary

This educational post, presented from my perspective as Dr. Alexander Jimenez, DC, APRN, FNP-BC, serves as a comprehensive analysis of the current state of healthcare and a call to action for a new paradigm of medicine. It begins by establishing the widespread dissatisfaction with the conventional “sick-care” system, a sentiment I observe daily in my clinical practice. The introduction outlines the journey we will take: a historical deep-dive into how medicine evolved into a symptom-focused, protocol-driven industry, heavily influenced by pharmaceutical and insurance interests. We then critically examine the physiological and clinical consequences of this model, using the misguided war on cholesterol as a prime example and linking its suppression to the rise of neurodegenerative diseases. The post deconstructs the “unholy alliance” between government, big pharma, and insurance companies that has prioritized profit over patient outcomes, stripping both clinicians and patients of their autonomy.

However, the core message is one of optimism and empowerment. We highlight the turning tide toward a more enlightened approach: empowered, personalized healthcare. The discussion champions the principles of root cause medicine, integrated therapies, and medical freedom. I elaborate on the foundational importance of hormone optimization, thyroid function, and nutrition as the pillars of this new model. Key recent developments, such as the FDA’s removal of the black box warning on estrogen and a renewed focus on nutrition in medical education, are presented as evidence that this new paradigm is gaining mainstream traction. The post emphasizes the need for a strong practitioner community and the power of following proven, evidence-based methods, which not only ensure superior patient outcomes but also provide a defensible standard of care. Ultimately, this text is a manifesto for clinicians to reclaim their role as healers, to move from being “disease managers” to “well-care providers,” and to partner with their patients to restore not just health, but vitality and life itself.

Conclusion

As we conclude this exploration on January 16, 2026, the message is unequivocal: the future of medicine is not a distant dream but a present-day reality we must actively create. The history of our profession is littered with well-intentioned but ultimately harmful “standards of care” that were later abandoned. We are currently living through another such era, where the management of symptoms has tragically eclipsed the pursuit of healing. The data is irrefutable: a system that costs trillions of dollars yet leaves us sicker and more medicated is a failed system.

The path forward requires a courageous departure from this failing model. It demands that we embrace critical thinking, prioritize root cause resolution, and treat the unique individual in front of us, not a set of numbers on a lab report. The convergence of science, a renewed focus on the patient-practitioner partnership, and the growing public demand for better health offers an unprecedented opportunity. We must have the humility to admit the old ways were wrong and the conviction to forge a new path grounded in integrated, personalized, and proactive care. This is not just about changing how we practice medicine; it’s about restoring the very soul of our profession and fulfilling the promise we made to our patients: to help them regain their health, their freedom, and their lives. The change starts with us, today.

Key Insights

  • The “Sick-Care” Model is Broken: The current healthcare system is designed for reactive disease management rather than proactive health promotion, resulting in a sicker, more medicated population despite record spending.
  • Symptom Suppression vs. Root Cause Resolution: A fundamental flaw in modern medicine is the focus on masking symptoms with pharmaceuticals (e.g., statins, hypertensives) rather than investigating and treating the underlying physiological imbalance.
  • The Danger of Flawed Dogma (e.g., cholesterol): The aggressive, widespread suppression of cholesterol, a molecule vital for brain health, hormone production, and immune function, is a prime example of how pharmaceutical-driven narratives can lead to devastating public health consequences, including a rise in dementia.
  • Medical Freedom is Paramount: True patient care requires that practitioners have the freedom to think critically and use evidence-based therapies without undue restrictions imposed by insurance companies or outdated regulatory guidance.
  • The Future is Integrated and Personalized: Optimal health is achieved through a holistic approach that integrates hormone optimization, thyroid health, nutrition, and lifestyle modifications tailored to the individual’s unique physiology.
  • Practitioner and Patient Empowerment is Key: The most powerful force for change is an educated patient base and a courageous community of practitioners who demand a better standard of care and partner together to achieve it.

Keywords

Integrative Medicine, Functional Medicine, Root Cause Medicine, Hormone Optimization, Bioidentical Hormone Replacement Therapy (BHRT), Thyroid Health, Personalized Medicine, Medical Freedom, Evidence-Based Medicine, Cholesterol, Statins, Alzheimer’s Disease, Nutrition, Proactive Healthcare, Well-Care, Patient Empowerment, Dr. Alexander Jimenez, El Paso Chiropractor, Nurse Practitioner.

References

  • Journal of the American Medical Association (JAMA), on the topic of nutrition in medical education.
  • Research on cholesterol’s role in dendritic cell communication (as of February 2025).
  • Data regarding insurance and pharmaceutical company profits post-ACA (2010-2023).
  • Data on the most prescribed medications in the United States (as of 2022).
  • Historical data and analysis of the Women’s Health Initiative (WHI) study.

Disclaimer

The information contained in this post is for educational and informational purposes only and is not intended as health or medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this webpage.

All individuals must obtain recommendations for their personal health situations from their own medical providers. The author and publisher of this post are not responsible for any adverse effects or consequences resulting from the use of any suggestions or procedures described hereafter. The views and opinions expressed in this post are those of the author and do not necessarily reflect the official policy or position of any other agency, organization, employer, or company.